Inhibitors of oplophorus luciferase-derived bioluminescent complexes

ABSTRACT

Compounds that may selectively inhibit  Oplophorus  luciferase-derived bioluminescent complexes, e.g., NanoBiT® bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the priority benefit of U.S. Provisional PatentApplication Ser. No. 62/679,205, filed on Jun. 1, 2018, which isincorporated herein by reference in its entirety.

TECHNICAL FIELD

The present disclosure is directed to compounds that may inhibitOplophorus luciferase-derived bioluminescent complexes, in particular abioluminescent complex of two or more non-luminescent peptide and/orpolypeptide units from an Oplophorus-derived luciferase.

BACKGROUND

Protein fragment complementation (PFC) or enzyme fragmentcomplementation (EFC) systems are valuable tools for monitoringco-localization and/or molecular interactions. In such systems,complementary amino acid chains, e.g., peptides or polypeptides, from areporter molecule, e.g., a bioluminescent protein or enzyme, are fusedto co-localizing and/or interacting molecules. Reporter molecules areroutinely used to monitor molecular events in the fields of biology,biochemistry, immunology, cell biology, and molecular biology.Luciferases based on the luciferase secreted from the deep-sea shrimp,Oplophorus gracilirostris, may be used as reporter molecules and havebeen shown to have advantageous characteristics including broadsubstrate specificity, high activity, and high quantum yield. Forexample, non-luminescent peptides and/or polypeptides units of anOplophorus luciferase variant can be fused to co-localizing/interactingmolecules (e.g., proteins). When the molecules co-localize and/orinteract, the non-luminescent peptide and/or polypeptide units associateto form a bioluminescent complex that, in the presence of a substrate(e.g., coelenterazine or coelenterazine derivative substrate), cangenerate a luminescent signal, which indicates theco-localization/interaction of the molecules. It may be furtheradvantageous, in certain applications, to control the luminescent signalfrom the Oplophorus luciferase-derived bioluminescent complexes.Selective inhibitors for such bioluminescent complexes are useful inluminescent assays. Luciferase inhibitors may be further derivatized toprovide desirable properties useful for studying enzyme activities andcellular processes.

SUMMARY

In one aspect, the disclosure provides a compound of formula (I), or asalt thereof:

wherein:

R¹ is an aryl, a cycloalkyl, a heteroaryl, a heterocycle, an arylalkyl,a cycloalkylalkyl, a heteroarylalkyl, or a heterocyclylalkyl, whereinthe aryl, cycloalkyl, heteroaryl, and heterocycle are optionallysubstituted with one or more R^(W), wherein each R^(W) is independentlyselected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl,halogen, —CN, —OR^(A), —C₁₋₁₀alkylene-OR^(A), —CO—R^(A),—C₁₋₁₀alkylene-CO—R^(A), —CO—OR^(A), —C₁₋₁₀alkylene-CO—OR^(A),—CO—NHR^(A), —C₁₋₁₀alkylene-CO—NHR^(A), —NR^(B)R^(C),—C₁₋₁₀alkylene-NR^(B)R^(C), —NH—CO—C₁₋₄alkyl,—C₁₋₁₀alkylene-NH—CO—C₁₋₄alkyl, phenyl, and phenyl substituted with 1,2, 3, or 4 R^(D) groups;

each R² is independently C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, halogen, —CN,—OR^(A), —C₁₋₄alkylene-OR^(A), —CO—R^(A), —C₁₋₄alkylene-CO—R^(A),—CO—OR^(A), —C₁₋₄alkylene-CO—OR^(A), —CO—NHR^(A),—C₁₋₄alkylene-CO—NR^(A), —NR^(B)R^(C), —C₁₋₄alkylene-NR^(B)R^(C),—NH—CO—C₁₋₄alkyl, —C₁₋₄alkylene-NH—CO—C₁₋₄alkyl, phenyl, phenylsubstituted with 1, 2, 3, or 4 R^(D) groups, —C≡C—R^(A), or—C≡C₁₋₄alkylene-OR^(A), or two R² together with the carbon atoms of the

moiety to which they are attached form a 5- or 6-membered fused ring;

each R³ is independently C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, halogen, —CN,—OR^(A), —C₁₋₄alkylene-OR^(A), —CO—R^(A), —CO—OR^(A), or —CO—NHR^(A), ortwo R³ together with the carbon atoms of the

moiety to which they are attached form a 5- or 6-membered fused ring;

R⁴ is H or C₁₋₄alkyl;

p is 0, 1, 2, 3, or 4;

q is 0, 1, 2, 3, or 4;

R^(A) at each occurrence is independently H, C₁₋₄alkyl, orC₁₋₄haloalkyl;

R^(B) and R^(C) at each occurrence are independently H or C₁₋₄alkyl, orR^(B) and R^(C) together with the N atom to which they are attached forma 5- or 6-membered heterocycle; and

R^(D) at each occurrence is independently C₁₋₄alkyl, —OC₁₋₄alkyl, —CN,or halogen.

In one aspect, the disclosure provides a method of inhibiting anOplophorus luciferase-derived bioluminescent complex, the methodcomprising contacting the bioluminescent complex with a compounddescribed herein.

In one aspect, the disclosure provides a method for modulatingluminescence of an Oplophorus luciferase-derived bioluminescent complexin a sample, the method comprising,

-   -   (a) contacting the sample with a coelenterazine substrate and a        compound described herein, and    -   (b) detecting luminescence in the sample,    -   wherein the compound causes a decrease in the luminescence from        the bioluminescent complex.

In one aspect, the disclosure provides a method to detect an interactionor co-localization between a first molecule and a second molecule in asample, the method comprising:

-   -   (a) contacting a sample with a coelenterazine substrate and a        compound described herein, wherein the sample comprises:        -   (i) a first fusion, wherein the first fusion comprises a            non-luminescent peptide of an Oplophorus-derived luciferase            and a first molecule; and        -   (ii) a second fusion, wherein the second fusion comprises a            non-luminescent polypeptide of an Oplophorus-derived            luciferase and a second molecule, wherein the            non-luminescent polypeptide is capable of forming a            bioluminescent complex with the non-luminescent peptide; and    -   (b) detecting luminescence in the sample,    -   wherein the detection of luminescence indicates an interaction        or co-localization between the first molecule and the second        molecule.

In one aspect, the disclosure provides a method to detect an interactionor co-localization between a first molecule and a second molecule in asample, the method comprising:

-   -   (a) contacting a sample with a coelenterazine substrate and a        compound described herein, wherein the sample comprises:        -   (i) a first polynucleotide encoding a first fusion, wherein            the first fusion comprises a non-luminescent peptide of an            Oplophorus-derived luciferase and a first molecule; and        -   (ii) a second polynucleotide encoding a second fusion,            wherein the second fusion comprises a non-luminescent            polypeptide of an Oplophorus-derived luciferase and a second            molecule, wherein the non-luminescent polypeptide is capable            of forming a bioluminescent complex with the non-luminescent            peptide; and    -   (b) detecting luminescence in the sample,

wherein the detection of luminescence indicates an interaction orco-localization between the first molecule and the second molecule.

In one aspect, the disclosure provides a method to detect an interactionor co-localization of a first molecule and a second molecule in asample, the method comprising:

(a) contacting a sample with a non-luminescent polypeptide of anOplophorus-derived luciferase, a coelenterazine substrate, and acompound described herein, wherein the sample comprises:

-   -   (i) a first polynucleotide encoding a first fusion, wherein the        first fusion comprises an non-luminescent peptide of an        Oplophorus-derived luciferase and a first molecule, wherein the        non-luminescent peptide is capable of forming a bioluminescent        complex with the non-luminescent polypeptide; and    -   (ii) a second polynucleotide encoding a second fusion, wherein        the second fusion comprises a fluorescent acceptor molecule and        a second molecule; and

(b) detecting bioluminescence resonance energy transfer (BRET) in thesample indicating an interaction or co-localization of the firstmolecule and the second molecule.

In one aspect, the disclosure provides a method to detect an interactionor co-localization of a first molecule and a second molecule in asample, the method comprising:

(a) contacting a sample with a non-luminescent peptide of anOplophorus-derived luciferase, a coelenterazine substrate, and acompound described herein, wherein the sample comprises:

-   -   (i) a first polynucleotide encoding a first fusion, wherein the        first fusion comprises an non-luminescent polypeptide of an        Oplophorus-derived luciferase and a first molecule, wherein the        non-luminescent polypeptide is capable of forming a        bioluminescent complex with the non-luminescent peptide; and    -   (ii) a second polynucleotide encoding a second fusion, wherein        the second fusion comprises a fluorescent acceptor molecule and        a second molecule; and

(b) detecting bioluminescence resonance energy transfer (BRET) in thesample indicating an interaction or co-localization of the firstmolecule and the second molecule.

In one aspect, the disclosure provides a method to detect interaction orco-localization of molecules in a sample, the method comprising:

(a) contacting a sample with a coelenterazine substrate and a compounddescribed herein, wherein the sample comprises:

-   -   (i) a first fusion comprising a non-luminescent polypeptide of        an Oplophorus-derived luciferase and a first molecule;    -   (ii) a second fusion comprising a non-luminescent peptide of an        Oplophorus-derived luciferase and a second molecule, wherein the        non-luminescent peptide is capable of forming a bioluminescent        complex with the non-luminescent polypeptide; and    -   (iii) a third fusion comprising a fluorescent acceptor molecule        and a third molecule; and

(b) detecting bioluminescence resonance energy transfer (BRET) in thesample, indicating an interaction or co-localization between the firstmolecule, second molecule, and third molecule in the sample.

In one aspect, the disclosure provides a method to detect a molecule ofinterest in a sample, the method comprising:

(a) contacting a sample comprising the molecule of interest fused to anon-luminescent peptide of an Oplophorus-derived luciferase with

-   -   (i) a coelenterazine substrate;    -   (ii) a compound described herein; and    -   (iii) a non-luminescent polypeptide of an Oplophorus-derived        luciferase, wherein the non-luminescent polypeptide is capable        of forming a bioluminescent complex with the non-luminescent        peptide; and

(b) detecting luminescence in the sample,

wherein detection of luminescence indicates formation of abioluminescent complex between the non-luminescent peptide and thenon-luminescent polypeptide.

In one aspect, the disclosure provides a method to detect a molecule ofinterest in a sample, the method comprising:

(a) contacting a sample comprising the molecule of interest fused to anon-luminescent polypeptide of an Oplophorus-derived luciferase with

-   -   (i) a coelenterazine substrate;    -   (ii) a compound disclosed herein; and    -   (iii) a non-luminescent peptide of an Oplophorus-derived        luciferase, wherein the non-luminescent peptide is capable of        forming a bioluminescent complex with the non-luminescent        polypeptide; and

(b) detecting luminescence in the sample,

wherein detection of luminescence indicates formation of abioluminescent complex between the non-luminescent peptide and thenon-luminescent polypeptide.

In one aspect, the disclosure provides a method to detect a molecule ofinterest in a sample, the method comprising:

(a) contacting a sample comprising the molecule of interest fused to anon-luminescent peptide of an Oplophorus-derived luciferase with

-   -   (i) a coelenterazine substrate;    -   (ii) a compound described herein; and    -   (iii) a fusion comprising a non-luminescent polypeptide of an        Oplophorus-derived luciferase and a fluorescent moiety, wherein        the non-luminescent polypeptide is capable of forming a        bioluminescent complex with the non-luminescent peptide; and    -   (b) detecting bioluminescence resonance energy transfer (BRET)        in the sample, indicating detection of the molecule.

In one aspect, the disclosure provides a method to detect a molecule ofinterest in a sample, the method comprising:

(a) contacting a sample comprising the molecule of interest fused to anon-luminescent polypeptide of an Oplophorus-derived luciferase with

-   -   (i) a coelenterazine substrate;    -   (ii) a compound disclosed herein; and    -   (iii) a fusion comprising a non-luminescent peptide of an        Oplophorus-derived luciferase and a fluorescent moiety, wherein        the non-luminescent peptide is capable of forming a        bioluminescent complex with the non-luminescent polypeptide; and

(b) detecting bioluminescence resonance energy transfer (BRET) in thesample, indicating detection of the molecule.

In one aspect, the disclosure provides a bioluminescence resonanceenergy transfer (BRET) system comprising:

(a) a first fusion comprising a non-luminescent peptide of anOplophorus-derived luciferase and a first molecule;

(b) a second fusion comprising a non-luminescent polypeptide of anOplophorus-derived luciferase and a fluorescent moiety, wherein thenon-luminescent polypeptide is capable of forming a bioluminescentcomplex with the non-luminescent peptide;

(c) a coelenterazine substrate; and

(d) a compound described herein.

In one aspect, the disclosure provides a bioluminescence resonanceenergy transfer (BRET) system comprising:

(a) a first fusion comprising a non-luminescent polypeptide of anOplophorus-derived luciferase and a first molecule;

(b) a second fusion comprising a non-luminescent peptide of anOplophorus-derived luciferase and a fluorescent moiety, wherein thenon-luminescent peptide is capable of forming a bioluminescent complexwith the non-luminescent polypeptide;

(c) a coelenterazine substrate; and

(d) a compound described herein.

In one aspect, the disclosure provides a bioluminescence resonanceenergy transfer (BRET) system comprising:

(a) a first fusion comprising a first molecule and a non-luminescentpeptide of an Oplophorus-derived luciferase;

(b) a second fusion comprising a second molecule and a fluorescentacceptor molecule;

(c) a non-luminescent polypeptide of Oplophorus-derived luciferasecapable of forming a bioluminescent complex with the non-luminescentpolypeptide of an Oplophorus-derived luciferase;

(d) a coelenterazine substrate; and

(e) a compound described herein.

In one aspect, the disclosure provides a bioluminescence resonanceenergy transfer (BRET) system comprising:

(a) a first fusion comprising a first molecule and a non-luminescentpolypeptide of an Oplophorus-derived luciferase;

(b) a second fusion comprising a second molecule and a fluorescentacceptor molecule;

(c) a non-luminescent peptide of Oplophorus-derived luciferase capableof forming a bioluminescent complex with the non-luminescent polypeptideof an Oplophorus-derived luciferase;

(d) a coelenterazine substrate; and

(e) a compound described herein.

In one aspect, the disclosure provides a kit comprising:

(a) a compound described herein;

(b) a first polynucleotide encoding a non-luminescent peptide of anOplophorus-derived luciferase; and

(c) a second polynucleotide encoding a non-luminescent polypeptide of anOplophorus-derived luciferase, wherein the non-luminescent polypeptideis capable of forming a bioluminescent complex with the non-luminescentpeptide.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1C show the inhibition of bioluminescent complexes by exemplarycompounds of the present invention. FIG. 1A shows inhibition of theNanoBiT® HiBiT/LgBiT bioluminescent complex. FIG. 1B shows theinhibition of the NanoBiT® SmBiT/LgBiT bioluminescent complex. FIG. 1Cis a bar graph showing the calculated IC₅₀ values of the exemplarycompounds shown in FIGS. 1A and 1B.

FIG. 2 compares the NANOLUC® (Nluc) inhibitory activity of exemplarycompounds of the present invention to PBI-6096, a known Nluc inhibitor.JRW-1004, HL-0005, and HL-0010 do not show any appreciable inhibitionagainst NanoLuc indicating selective inhibition for Oplophorusluciferase-derived bioluminescent complexes.

FIGS. 3A-3B show the inhibition of bioluminescent complexes in cells byexemplary compounds of the present invention. FIG. 3A shows inhibitionof NanoBiT® HiBit/LgBit bioluminescent complex with HL-0005 in acellular context. FIG. 3B compares IC₅₀ values in lytic and non-lyticconditions indicating HL-0005 is mostly cell permeable.

DETAILED DESCRIPTION

The disclosed compounds may selectively inhibit Oplophorus-luciferasederived bioluminescent complexes. For example, the disclosed compoundsmay selectively inhibit a Oplophorus-luciferase derived bioluminescentcomplex comprising: (a) a peptide comprising a peptide amino acidsequence having less than 100% sequence identity (e.g., >99%, <95%,<90%, <80%, <70%, <60%, <50%, etc.) and greater than 40%(e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%)with SEQ ID NO: 2; and (b) a polypeptide comprising a polypeptide aminoacid sequence having less than 100% (e.g., >99%, <95%, <90%, <80%, <70%,<60%, <50%, etc.) and greater than 40%(e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%)sequence identity with SEQ ID NO: 3, wherein the bioluminescent complexexhibits detectable luminescence in the presence of a coelenterazinesubstrate. In certain embodiments, the disclosed compounds mayselectively inhibit a Oplophorus-luciferase derived bioluminescentcomplex: (a) a peptide comprising a peptide amino acid sequence SEQ IDNO: 4 or SEQ ID NO: 6; and (b) a polypeptide comprising a polypeptideamino acid sequence having SEQ ID NO: 5, wherein the bioluminescentcomplex exhibits detectable luminescence in the presence of acoelenterazine substrate. Exemplary bioluminescent complexes that may beinhibited using the disclosed compounds are described in U.S. Pat. Nos.9,797,889 and 9,797,890, the entire contents of which are incorporatedby reference in their entirety. For example, the disclosed compounds mayselectively inhibit a NanoBiT® HiBiT/LgBiT bioluminescent complex. Asanother example, the disclosed compounds may selectively inhibit aNanoBiT® LgBiT/SmBiT bioluminescent complex.

Due to their stabilities, the potential to be excreted from cells, andthe presence of cell debris arising from culturing cells, it may beadvantageous to use the selective inhibitors of the present invention tosuppress the luminescence from Oplophorus luciferase-derivedbioluminescent complexes in certain applications. For example, inapplications involving temporal multiplexing of multiple luminescentsystems, it can be beneficial to have selective inhibitors for eachsystem to allow for the measurement and/or detection of only oneluminescent signal at a time. Additionally, in some plate-based assays,a certain amount of luciferase may be excreted from cells or may bepresent in culture media from cellular debris. An extracellularinhibitor compound would allow for luminescence from luciferase in mediato be selectively suppressed and may, therefore, help to improve thesignal-to-background ratio in certain assays.

In particular embodiments, the light generated from NanoBiT®bioluminescent complexes may be selectively suppressed by the compoundsdisclosed herein. Advantageously, such selective inhibition may be usedto enable temporal multiplexing of multiple bioluminescent systems suchas NanoBiT and NanoLuc. Further, the disclosed compounds provideselective bioluminescent suppression (e.g., intracellular orextracellular selectivity) to enable certain plate-based luminescentassays. The compounds may compete for binding of the coelenterazinesubstrates of the luciferases and can be modified to produce bothcell-permeable and cell-impermeable inhibitors.

1. Definitions

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art. In case of conflict, the present document, includingdefinitions, will control. Preferred methods and materials are describedbelow, although methods and materials similar or equivalent to thosedescribed herein can be used in practice or testing of the presentinvention. All publications, patent applications, patents and otherreferences mentioned herein are incorporated by reference in theirentirety. The materials, methods, and examples disclosed herein areillustrative only and not intended to be limiting.

The terms “comprise(s),” “include(s),” “having,” “has,” “can,”“contain(s),” and variants thereof, as used herein, are intended to beopen-ended transitional phrases, terms, or words that do not precludethe possibility of additional acts or structures. The singular forms“a,” “and” and “the” include plural references unless the contextclearly dictates otherwise. The present disclosure also contemplatesother embodiments “comprising,” “consisting of” and “consistingessentially of,” the embodiments or elements presented herein, whetherexplicitly set forth or not.

As used herein, the term “substituent” or “suitable substituent” isintended to mean a chemically acceptable functional group e.g., a moietythat does not negate the activity of the inventive compounds.Illustrative examples of suitable substituents include, but are notlimited to halo groups, perfluoroalkyl groups, perfluoroalkoxy groups,alkyl groups, alkenyl groups, alkynyl groups, hydroxy groups, halogroups, oxo groups, mercapto groups, alkylthio groups, alkoxy groups,nitro groups, azidealkyl groups, sulfonic acid groups, aryl orheteroaryl groups, aryloxy or heteroaryloxy groups, aralkyl orheteroaralkyl groups, aralkoxy or heteroaralkoxy groups, HO—(C═O)—groups, heterocylic groups, cycloalkyl groups, amino groups, alkyl- anddialkyl-amino groups, carbamoyl groups, alkylcarbonyl groups,alkylcarbonyloxy groups, alkoxycarbonyl groups, alkylaminocarbonylgroups, dialkylamino carbonyl groups, arylcarbonyl groups,aryloxycarbonyl groups, alkylsulfonyl groups, arylsulfonyl groups andthe like. The substituents can be substituted by additionalsubstituents. The substituents can also be in salt forms (e.g., asulfonic acid group can be in the form of a sulfonate group.

Definitions of specific functional groups and chemical terms aredescribed in more detail below. For purposes of this disclosure, thechemical elements are identified in accordance with the Periodic Tableof the Elements, CAS version, Handbook of Chemistry and Physics, 75^(th)Ed., inside cover, and specific functional groups are generally definedas described therein. Additionally, general principles of organicchemistry, as well as specific functional moieties and reactivity, aredescribed in Organic Chemistry, Thomas Sorrell, University ScienceBooks, Sausalito, 1999; Smith and March March's Advanced OrganicChemistry, 5^(th) Edition, John Wiley & Sons, Inc., New York, 2001;Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., NewYork, 1989; Carruthers, Some Modern Methods of Organic Synthesis, 3^(rd)Edition, Cambridge University Press, Cambridge, 1987; the entirecontents of each of which are incorporated herein by reference.

As used herein, the term “alkenyl” refers a straight or branchedhydrocarbon chain containing from 2 to 10 carbons and containing atleast one carbon-carbon double bond formed by the removal of twohydrogens. Representative examples of alkenyl include, but are notlimited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl,4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.Alkenyl groups of the present invention may be unsubstituted orsubstituted by one or more suitable substituents, preferably 1 to 3suitable substituents, as defined above.

As used herein, the term “alkoxy” refers to an alkyl group, as definedherein, appended to the parent molecular moiety through an oxygen atom.Representative examples of alkoxy include, but are not limited to,methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, andhexyloxy.

As used herein, the term “alkoxyalkoxy” refers to an alkoxy group, asdefined herein, appended to the parent molecular moiety through anotheralkoxy group, as defined herein. Representative examples of alkoxyalkoxyinclude, but are not limited to, tert-butoxymethoxy, 2-ethoxyethoxy,2-methoxyethoxy, and methoxymethoxy.

The term “alkoxyalkoxyalkyl” as used herein, means an alkoxyalkoxygroup, as defined herein, appended to the parent molecular moietythrough an alkylene group, as defined herein. Representative examples ofalkoxyalkoxyalkyl include, but are not limited to,tert-butoxymethoxymethyl, ethoxymethoxymethyl, (2-methoxyethoxy)methyl,and 2-(2-methoxyethoxy)ethyl.

As used herein, the term “alkoxyalkyl” refers to an alkoxy group, asdefined herein, appended to the parent molecular moiety through an alkylgroup, as defined herein. Representative examples of alkoxyalkylinclude, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl,2-methoxyethyl, and methoxymethyl.

As used herein, the term “alkoxycarbonyl” refers to an alkoxy group, asdefined herein, appended to the parent molecular moiety through acarbonyl group, as defined herein. Representative examples ofalkoxycarbonyl include, but are not limited to, methoxycarbonyl,ethoxycarbonyl, and tert-butoxycarbonyl.

The term “alkoxycarbonylalkyl” as used herein, means an alkoxycarbonylgroup, as defined herein, appended to the parent molecular moietythrough an alkylene group, as defined herein. Representative examples ofalkoxycarbonylalkyl include, but are not limited to,ethoxycarbonylmethyl, 3-methoxycarbonylpropyl, 4-ethoxycarbonylbutyl,and 2-tert-butoxycarbonylethyl.

As used herein, the term “alkyl” refers to a linear or branchedhydrocarbon radical, suitably having 1 to 30 carbon atoms, 1 to 12carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbonatoms, or 1 to 4 carbon atoms. The term “C₁-C₈-alkyl” is defined toinclude alkyl groups having 1, 2, 3, 4, 5, 6, 7 or 8 carbons in a linearor branched arrangement. For example, “C₁-C₈-alkyl” specificallyincludes methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl,iso-butyl, tert-butyl, pentyl (e.g., n-pentyl), hexyl (e.g., n-hexyl),heptyl (e.g., n-heptyl) and octyl (e.g., n-octyl). The term“C₁-C₆-alkyl” is defined to include alkyl groups having 1, 2, 3, 4, 5,or 6 carbons in a linear or branched arrangement. For example,“C₁-C₆-alkyl” specifically includes methyl, ethyl, n-propyl, iso-propyl,n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl (e.g., n-pentyl), andhexyl (e.g., n-hexyl). The term “C₁-C₄-alkyl” is defined to includealkyl groups having 1, 2, 3, or 4 carbons in a linear or branchedarrangement. For example, “C₁-C₄-alkyl” specifically includes methyl,ethyl, n-propyl, i-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl.Alkyl groups of the present invention may be unsubstituted orsubstituted by one or more suitable substituents, such as 1 to 3suitable substituents, as defined above. For example, an alkyl group canbe substituted with one or more halo substituents to form a haloalkylgroup, or with one or more hydroxy substituents to form a hydroxyalkylgroup, or with one or more alkoxy groups to form an alkoxyalkyl group.

As used herein, the term “alkylamino” refers to an alkyl group, asdefined herein, appended to the parent molecular moiety through an aminogroup, as defined herein. Representative examples of alkylamino include,but are not limited to, methylamino, ethylamino, iso-propylamino,butyl-amino and sec-butylamino.

As used herein, the term “alkylaminoalkyl” refers to an alkyl group, asdefined herein, appended to the parent molecular moiety through anaminoalkyl group, as defined herein. Representative examples ofalkylaminoalkyl groups include, but are not limited to, methylaminoethyland methylamino-2-propyl.

As used herein, the term “alkylcarbonyl” refers to an alkyl group, asdefined herein, appended to the parent molecular moiety through acarbonyl group, as defined herein. Representative examples ofalkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl,2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.

As used herein, the term “alkylcarbonylalkyl” refers to an alkylcarbonylgroup, as defined herein, appended to the parent molecular moietythrough an alkyl group, as defined herein.

As used herein, the term “alkylcarbonylalkylamido” refers to analkylcarbonyl group, as defined herein, appended to the parent molecularmoiety through an alkylamido group, as defined herein.

The term “alkylene” means a divalent group derived from a saturated,straight or branched chain hydrocarbon of from 1 to 10 carbon atoms.Representative examples of alkylene include, but are not limited to,—CH₂—, —CH(CH₃)—, —C(CH₃)₂—, —CH₂CH₂—, —CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂—,—CH₂C(CH₃)₂—, and —CH₂CH(CH₃)CH₂—.

As used herein, the term “alkynyl” refers to a straight or branchedhydrocarbon radical having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbons, andhaving one or more carbon-carbon triple bonds. Alkynyl groups of thepresent invention include, but are not limited to, ethynyl, propynyl,and butynyl. Alkynyl groups of the present invention may beunsubstituted or substituted by one or more suitable substituents,preferably 1 to 3 suitable substituents, as defined above.

As used herein, the term “amido” refers to an amino group appended tothe parent molecular moiety through a carbonyl group, as defined herein(i.e., —CONH₂). The term “alkylamido,” as used herein, refers to analkylamino group or dialkylamino group appended to the parent molecularmoiety through a carbonyl group, as defined herein. Representativeexamples of alkylamido include, but are not limited to,methylaminocarbonyl, dimethylaminocarbonyl, ethylmethylaminocarbonyl,and n-hexylaminocarbonyl.

As used herein, the term “amino” refers to an —NH₂ group.

As used herein, the term “aminoalkyl” refers to at least one aminogroup, as defined herein, appended to the parent molecular moietythrough an alkyl group, as defined herein. Representative examples ofaminoalkyl include, but are not limited to, aminomethyl, 2-aminoethyl,3-aminopropyl, 4-aminobutyl, 5-aminopentyl, and 6-aminohexyl.

As used herein, the term “aminoalkylamido” refers to at least one aminogroup, as defined herein, appended to the parent molecular moietythrough an alkylamido group, as defined herein.

As used herein, the term “amino protecting group,” refers to a moietythat prevents chemical reactions from occurring on the nitrogen atom towhich that protecting group is attached. An amino protecting group mustalso be removable by a chemical reaction. Such groups are well known inthe art and include those described in detail in Protecting Groups inOrganic Synthesis, T. W. Greene and P. G. M. Wuts, 3^(rd) edition, JohnWiley & Sons, 1999, the entirety of which is incorporated herein byreference. Suitable amino protecting groups include, but are not limitedto, carbobenzyloxy (—NHCO—OCH₂C₆H₅ or —NH-Cbz); t-butyloxycarbonyl(—NHCO—OC(CH₃)₃ or —NH-Boc); 9-fluorenylmethyloxycarbonyl (—NH—Fmoc),2,2,2-trichloroethyloxycarbonyl (—NH-Troc), and allyloxycarbonyl(—NH-Alloc). In each of the above, the —NH— represents the nitrogen fromthe amino group that is being protected.

As used herein, the term “aminoluciferin” refers to(4S)-2-(6-amino-1,3-benzothiazol-2-yl)-4,5-dihydrothiazole-4-carboxylicacid, or a substituted analog of this molecule.

As used herein, the term “aryl” means monocyclic, bicyclic, or tricyclicaromatic radicals. Representative examples of the aryl groups include,but are not limited to, phenyl, dihydroindenyl, indenyl, naphthyl,dihydronaphthalenyl, and tetrahydronaphthalenyl. Aryl groups of thepresent invention may be optionally substituted by one or more suitablesubstituents, preferably 1 to 5 suitable substituents, as defined above.The aryl as used herein includes a phenyl appended to the parentmolecular moiety and fused to a cycloalkyl group (e.g., indanyl or5,6,7,8-tetrahydronaphthalen-2-yl), a phenyl group (i.e., naphthyl), ora non-aromatic heterocycle (e.g., benzo[d][1,3]dioxol-5-yl).

As used herein, the term “arylalkyl” refers to an aryl group, as definedherein, appended to the parent molecular moiety through an alkyl group,as defined herein. Representative examples of arylalkyl include, but arenot limited to, phenylmethyl (i.e. benzyl) and phenylethyl.

As used herein, the term “arylcarbonyl” refers to an aryl group, asdefined herein, appended to the parent molecular moiety through acarbonyl group, as defined herein.

As used herein, the term “carbonyl” or “(C═O)” (as used in phrases suchas alkylcarbonyl, alkyl-(C═O)— or alkoxycarbonyl) refers to the joinderof the >C═O moiety to a second moiety such as an alkyl or amino group(i.e. an amido group). Alkoxycarbonylamino (i.e. alkoxy(C═O)—NH—) refersto an alkyl carbamate group. The carbonyl group is also equivalentlydefined herein as (C═O). Alkylcarbonylamino refers to groups such asacetamide.

As used herein, the term “carboxy” refers to a —C(O)OH group.

As used herein, the term “carboxyalkyl” refers to a carboxy group asdefined herein, appended to the parent molecular moiety through an alkylgroup as defined herein.

As used herein, the term “carboxyalkylamido” refers to a carboxyalkylgroup as defined herein, appended to the parent molecular moiety throughan amido group as defined herein.

As used herein, the term “cycloalkyl” refers to a mono, bicyclic ortricyclic carbocyclic radical (e.g., cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl,cyclopentenyl, cyclohexenyl, bicyclo[2.2.1]heptanyl,bicyclo[3.2.1]octanyl and bicyclo[5.2.0]nonanyl, etc.); optionallycontaining 1 or 2 double bonds. Cycloalkyl groups of the presentinvention may be unsubstituted or substituted by one or more suitablesubstituents, preferably 1 to 5 suitable substituents, as defined above.

As used herein, the term “cycloalkylalkyl” refers to a cycloalkyl group,as defined herein, appended to the parent molecular moiety through analkyl group, as defined herein. Representative examples ofcycloalkylalkyl include, but are not limited to, cyclohexylmethyl.

As used herein, the term “cycloalkylamido” refers to a cycloalkyl group,as defined herein, appended to the parent molecular moiety through anamido group, as defined herein.

As used herein, the term “dialkylamino” refers to two independentlyselected alkyl groups, as defined herein, appended to the parentmolecular moiety through an amino group, as defined herein.Representative examples of dialkylamino include, but are not limited to,N,N-dimethylamino, N-ethyl-N-methylamino, and N-isopropyl-N-methylamino.

As used herein, the term “dialkylaminoalkyl” refers to a dialkylaminogroup, as defined herein, appended to the parent molecular moietythrough an alkyl group, as defined herein. Representative examples ofdialkylaminoalkyl include, but are not limited to,N,N-dimethylaminoethyl and N,N-methyl(2-propyl)aminoethyl.

As used herein, the term “dialkylaminoalkylamido” refers to adialkylamino group, as defined herein, appended to the parent molecularmoiety through an alkylamido group, as defined herein.

As used herein, the term “halogen” or “halo” refers to a fluoro, chloro,bromo or iodo radical.

As used herein, the term “haloalkoxy” refers to an alkoxy group, asdefined herein, substituted by one, two, three, or four halogen atoms.Representative examples of haloalkoxy include, but are not limited to,chloromethoxy, 2-fluoroethoxy, trifluoromethoxy, and pentafluoroethoxy.

As used herein, the term “haloalkyl” refers to an alkyl group, asdefined herein, substituted by one, two, three, or four halogen atoms.Representative examples of haloalkyl include, but are not limited to,chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl,2-chloro-3-fluoropentyl, and 4,4,4,-trifluorobutyl.

As used herein, the term “heteroaryl” refers to a monocyclic heteroarylor a bicyclic heteroaryl. The monocyclic heteroaryl is a five- orsix-membered ring. The five-membered ring contains two double bonds. Thefive-membered ring may contain one heteroatom selected from O or S; orone, two, three, or four nitrogen atoms and optionally one oxygen orsulfur atom. The six-membered ring contains three double bonds and one,two, three or four nitrogen atoms. Representative examples of monocyclicheteroaryl include, but are not limited to, furanyl, imidazolyl,isoxazolyl, isothiazolyl, oxadiazolyl, 1,3-oxazolyl, pyridinyl,pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl,thiadiazolyl, 1,3-thiazolyl, thienyl, triazolyl, and triazinyl. Thebicyclic heteroaryl includes a monocyclic heteroaryl fused to a phenyl,or a monocyclic heteroaryl fused to a monocyclic cycloalkyl, or amonocyclic heteroaryl fused to a monocyclic cycloalkenyl, or amonocyclic heteroaryl fused to a monocyclic heteroaryl, or a monocyclicheteroaryl fused to a monocyclic heterocycle. Representative examples ofbicyclic heteroaryl groups include, but are not limited to,benzofuranyl, benzothienyl, benzoxazolyl, benzimidazolyl,benzoxadiazolyl, 6,7-dihydro-1,3-benzothiazolyl,imidazo[1,2-a]pyridinyl, indazolyl, indolyl, isoindolyl, isoquinolinyl,naphthyridinyl, pyridoimidazolyl, quinazolinyl, quinolinyl,thiazolo[5,4-b]pyridin-2-yl, thiazolo[5,4-d]pyrimidin-2-yl,5,6,7,8-tetrahydroquinolin-5-yl, cyclopenta[b]thiophen-2-yl, and4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl. Heteroaryl groups of thepresent invention may be unsubstituted or substituted by one or moresuitable substituents, preferably 1 to 5 suitable substituents, asdefined above.

As used herein, the term “heteroarylalkyl” refers to a heteroaryl group,as defined herein, appended to the parent molecular moiety through analkyl group, as defined herein. Representative examples ofheteroarylalkyl include, but are not limited to, fur-3-ylmethyl,1H-imidazol-2-ylmethyl, 1H-imidazol-4-ylmethyl, 1-(pyridin-4-yl)ethyl,pyridin-3-ylmethyl, 6-chloropyridin-3-ylmethyl, pyridin-4-ylmethyl,(6-(trifluoromethyl)pyridin-3-yl)methyl, (6-(cyano)pyridin-3-yl)methyl,(2-(cyano)pyridin-4-yl)methyl, (5-(cyano)pyridin-2-yl)methyl,(2-(chloro)pyridin-4-yl)methyl, pyrimidin-5-ylmethyl,2-(pyrimidin-2-yl)propyl, thien-2-ylmethyl, and thien-3-ylmethyl.

As used herein, the term “heterocycle” or “heterocyclyl” refers to amonocyclic heterocycle, a bicyclic heterocycle, or a tricyclicheterocycle. The monocyclic heterocycle is a three-, four-, five-, six-,seven-, or eight-membered ring containing at least one heteroatomindependently selected from the group consisting of oxygen, nitrogen,phosphorus and sulfur. The three- or four-membered ring contains zero orone double bond, and one heteroatom selected from the group consistingof oxygen, nitrogen, phosphorus and sulfur. The five-membered ringcontains zero or one double bond and one, two or three heteroatomsselected from the group consisting of oxygen, nitrogen, phosphorus andsulfur. The six-membered ring contains zero, one or two double bonds andone, two, or three heteroatoms selected from the group consisting ofoxygen, nitrogen, phosphorus and sulfur. The seven- and eight-memberedrings contains zero, one, two, or three double bonds and one, two, orthree heteroatoms selected from the group consisting of oxygen,nitrogen, phosphorus and sulfur. Representative examples of monocyclicheterocycles include, but are not limited to, azetidinyl, azepanyl,aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl,1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl,isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl,oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, phosphinane,piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl,pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl,tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothienyl,thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl,thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone),thiopyranyl, trithianyl, and 2,5-dioxo-pyrrolidinyl. The bicyclicheterocycle is a monocyclic heterocycle fused to a phenyl group, or amonocyclic heterocycle fused to a monocyclic cycloalkyl, or a monocyclicheterocycle fused to a monocyclic cycloalkenyl, or a monocyclicheterocycle fused to a monocyclic heterocycle, or a bridged monocyclicheterocycle ring system in which two non-adjacent atoms of the ring arelinked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, or analkenylene bridge of two, three, or four carbon atoms. Representativeexamples of bicyclic heterocycles include, but are not limited to,benzopyranyl, benzothiopyranyl, chromanyl, 2,3-dihydrobenzofuranyl,2,3-dihydrobenzothienyl, azabicyclo[2.2.1]heptyl (including2-azabicyclo[2.2.1]hept-2-yl), 2,3-dihydro-1H-indolyl, isoindolinyl,octahydrocyclopenta[c]pyrrolyl, octahydropyrrolopyridinyl,9-phosphabicyclo[3.3.1]nonane, 8-phosphabicyclo[3.2.1]octane, andtetrahydroisoquinolinyl. Tricyclic heterocycles are exemplified by abicyclic heterocycle fused to a phenyl group, or a bicyclic heterocyclefused to a monocyclic cycloalkyl, or a bicyclic heterocycle fused to amonocyclic cycloalkenyl, or a bicyclic heterocycle fused to a monocyclicheterocycle, or a bicyclic heterocycle in which two non-adjacent atomsof the bicyclic ring are linked by an alkylene bridge of 1, 2, 3, or 4carbon atoms, or an alkenylene bridge of two, three, or four carbonatoms. Examples of tricyclic heterocycles include, but are not limitedto, octahydro-2,5-epoxypentalene,hexahydro-2H-2,5-methanocyclopenta[b]furan,hexahydro-1H-1,4-methanocyclopenta[c]furan, aza-admantane(1-azatricyclo[3.3.1.1^(3,7)]decane), oxa-adamantane(2-oxatricyclo[3.3.1.1^(3,7)]decane), and2,4,6-trioxa-8-phosphatricyclo[3.3.1.13,7]decane. Heterocyclic groups ofthe present invention may be unsubstituted or substituted by one or moresuitable substituents, preferably 1 to 3 suitable substituents, asdefined above. Heterocyclic groups of the present invention may containone or more oxo groups (═O) or thioxo (═S) groups attached to the ring.

As used herein, the term “heterocyclylalkyl” refers to a heterocyclylgroup, as defined herein, appended to the parent molecular moietythrough an alkyl group, as defined herein. Representative examples ofheterocyclylalkyl include, but are not limited to, piperidin-4-ylmethyl,piperazin-1-ylmethyl, 3-methyl-1-pyrrolidin-1-ylbutyl,(1R)-3-methyl-1-pyrrolidin-1-ylbutyl,(1S)-3-methyl-1-pyrrolidin-1-ylbutyl, and 3-morpholinopropyl.

As used herein, the term “heterocyclylamido” refers to a heterocyclylgroup, as defined herein, appended to the parent molecular moietythrough an amido group, as defined herein.

As used herein, the term “hydroxy” refers to an —OH group.

As used herein, the term “hydroxyalkoxy” refers to an alkoxy group, asdefined herein, substituted by at least one hydroxy group.Representative examples of hydroxyalkoxy include, but are not limitedto, hydroxyethoxy, and 2-hydroxypropoxy.

As used herein, the term “hydroxyalkyl” refers to an alkyl group, asdefined herein, substituted by at least one hydroxy group.Representative examples of hydroxyalkyl include, but are not limited to,hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypropyl,2,3-dihydroxypentyl, 4-hydroxybutyl, 2-ethyl-4-hydroxyheptyl,3,4-dihydroxybutyl, and 5-hydroxypentyl.

The term “hydroxyalkylamido” as used herein refers to a hydroxyalkylgroup attached to an amido group, e.g., -amido-alkyl-OH.

As used herein, the term “hydroxycarbonyl” refers to a hydroxy group, asdefined herein, appended to the parent molecular moiety through acarbonyl group, as defined herein.

As used herein, the term “methylenedioxy” refers to a —OCH₂O— groupwherein the oxygen atoms of the methylenedioxy are attached to theparent molecular moiety through two adjacent carbon atoms.

As used herein, the term “oxo” refers to a double bonded oxygen (═O)radical wherein the bond partner is a carbon atom. Such a radical canalso be thought as a carbonyl group.

As used herein, unless otherwise specified, the terms “peptide” and“polypeptide” refer to polymer compounds of two or more amino acidsjoined through the main chain by peptide amide bonds (—C(O)NH—). Theterm “peptide” typically refers to short amino acid polymers (e.g.,chains having fewer than 25 amino acids), whereas the term “polypeptide”typically refers to longer amino acid polymers (e.g., chains having morethan 25 amino acids).

A prefix attached to a multi-component substituent only applies to thefirst component it precedes. To illustrate, the term “cycloalkylalkyl”contains two components: alkyl and cycloalkyl. Thus, the C₁₋₁₀ prefix onC₁₋₁₀cycloalkylalkyl means that the alkyl component of thecycloalkylalkyl contains from 1 to 6 carbon atoms; the C₁-C₆-prefix doesnot describe the cycloalkyl component. To illustrate further, the termC₁₋₁₀haloalkyl refers to halomethyl, haloethyl, halopropyl, halobutyl,halopentyl, and halohexyl. To illustrate further, the prefix “halo” onhaloalkoxyalkyl indicates that only the alkoxy component of thealkoxyalkyl substituent is substituted with one or more halogenradicals. If the halogen substitution may only occur on the alkylcomponent, the substituent would instead be described as“alkoxyhaloalkyl.”

A substituent is “substitutable” if it comprises at least one carbon ornitrogen atom that is bonded to one or more hydrogen atoms. Thus, forexample, hydrogen, halogen, and cyano do not fall within thisdefinition. In addition, a sulfur atom in a heterocyclyl containing suchatom is substitutable with one or two oxo substituents.

If a substituent is described as being “substituted,” a non-hydrogenradical is in the place of hydrogen radical on a carbon or nitrogen ofthe substituent. Thus, for example, a substituted alkyl substituent isan alkyl substituent in which at least one non-hydrogen radical is inthe place of a hydrogen radical on the alkyl substituent. To illustrate,monofluoroalkyl is alkyl substituted with a fluoro radical, anddifluoroalkyl is alkyl substituted with two fluoro radicals. It shouldbe recognized that if there is more than one substitution on asubstituent, each non-hydrogen radical may be identical or different(unless otherwise stated).

When a substituent is referred to as “unsubstituted” or not referred toas “substituted” or “optionally substituted,” it means that thesubstituent does not have any substituents. If a substituent isdescribed as being “optionally substituted,” the substituent may beeither (1) unsubstituted or (2) substituted. If a substituent isdescribed as being optionally substituted with up to a particular numberof non-hydrogen radicals, which substituent may be either (1)unsubstituted; or (2) substituted by up to that particular number ofnon-hydrogen radicals or by up to the maximum number of substitutablepositions on the substituent, whichever is less. Thus, for example, if asubstituent is described as a heteroaryl optionally substituted with upto 3 non-hydrogen radicals, then any heteroaryl with less than 3substitutable positions would be optionally substituted by up to only asmany non-hydrogen radicals as the heteroaryl has substitutablepositions. To illustrate, tetrazolyl (which has only one substitutableposition) would be optionally substituted with up to one non-hydrogenradical. To illustrate further, if an amino nitrogen is described asbeing optionally substituted with up to 2 non-hydrogen radicals, then aprimary amino nitrogen will be optionally substituted with up to 2non-hydrogen radicals, whereas a secondary amino nitrogen will beoptionally substituted with up to only 1 non-hydrogen radical.

If substituents are described as being “independently selected” from agroup, each substituent is selected independent of the other. Eachsubstituent, therefore, may be identical to or different from the othersubstituent(s).

As used herein, the term “bioluminescence” or “luminescence” may referto light produced as a result of a reaction between an enzyme and asubstrate that generates light. Examples of such enzymes (bioluminescentenzymes) include Oplophorus luciferase, e.g., Oplophorousgracilirostris, firefly luciferase, e.g. Photinus pyralis or Photurispennsylvanica, click beetle luciferase, Renilla luciferase, cypridinaluciferase, Aequorin photoprotein, obelin photoprotein, and the like.

As used herein, the term “complex” refers to an assemblage or aggregateof molecules (e.g., peptides, polypeptides, etc.) in direct and/orindirect contact with one another. In one aspect, “contact,” or moreparticularly, “direct contact” means two or more molecules are closeenough so that attractive noncovalent interactions, such as Van der Waalforces, hydrogen bonding, ionic and hydrophobic interactions, and thelike, dominate the interaction of the molecules. In such an aspect, acomplex of molecules (e.g., a peptide and polypeptide) is formed underassay conditions such that the complex is thermodynamically favored(e.g., compared to a non-aggregated, or non-complexed, state of itscomponent molecules). As used herein the term “complex,” unlessdescribed as otherwise, refers to the assemblage of two or moremolecules (e.g., peptides, polypeptides, or a combination thereof).

The terms “bioluminescent complex” or “Oplophorus luciferase-derivedbioluminescent complex” as used interchangeably herein, refer to theassembled complex of two or more non-luminescent peptides and/ornon-luminescent polypeptides. The bioluminescent complex catalyzes orenables the conversion of a substrate for the bioluminescent complexinto an unstable form; the substrate subsequently emits light. Whenuncomplexed, two non-luminescent elements that form a bioluminescentcomplex may be referred to as a “non-luminescent pair.” If abioluminescent complex is formed by three or more non-luminescentpeptides and/or non-luminescent polypeptides, the uncomplexedconstituents of the bioluminescent complex may be referred to as a“non-luminescent group.” An Oplophorus luciferase-derived bioluminescentcomplex may include (a) a peptide comprising a peptide amino acidsequence having less than 100% sequence identity (e.g., >99%, <95%,<90%, <80%, <70%, <60%, <50%, etc.) and greater than 40%(e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%)with SEQ ID NO: 2; and (b) a polypeptide comprising a polypeptide aminoacid sequence having less than 100% identity (e.g., >99%, <95%, <90%,<80%, <70%, <60%, <50%, etc.) and greater than 40%(e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%)sequence identity with SEQ ID NO: 3, wherein the bioluminescent complexexhibits detectable luminescence. In certain embodiments, the presentinvention provides bioluminescent complexes comprising: (a) a peptidecomprising a peptide amino acid sequence having SEQ ID NO: 4 or 6; and(b) a polypeptide comprising a polypeptide amino acid sequence havingSEQ ID NO: 5, wherein the bioluminescent complex exhibits detectableluminescence. Exemplary Oplophorus luciferase-derived bioluminescentcomplexes include the NanoBliT® technology that includes a SmBiTnon-luminescent peptide (SEQ ID NO: 6), NanoBliT® HiBiT non-luminescentpeptide (SEQ ID NO: 4), and/or NanoBliT® LgBiT non-luminescentpolypeptide (SEQ ID NO: 5).

As used herein, the term “non-luminescent” refers to an entity (e.g.,peptide, polypeptide, complex, protein, etc.) that exhibits thecharacteristic of not emitting a detectable amount of light in thevisible spectrum (e.g., in the presence of a substrate). For example, anentity may be referred to as non-luminescent if it does not exhibitdetectable luminescence in a given assay. As used herein, the term“non-luminescent” is synonymous with the term “substantiallynon-luminescent. For example, a non-luminescent polypeptide (NLpoly) issubstantially non-luminescent, exhibiting, for example, a 10-fold ormore (e.g., 100-fold, 200-fold, 500-fold, 1×10³-fold, 1×10⁴-fold,1×10⁵-fold, 1×10⁶-fold, 1×10⁷-fold, etc.) reduction in luminescencecompared to a complex of the NLpoly with its non-luminescent complementpeptide. In some embodiments, an entity is “non-luminescent” if anylight emission is sufficiently minimal so as not to create interferingbackground for a particular assay.

As used herein, the terms “non-luminescent peptide” (e.g., NLpep) and“non-luminescent polypeptide” (e.g., NLpoly) refer to peptides andpolypeptides that exhibit substantially no luminescence (e.g., in thepresence of a substrate), or an amount that is beneath the noise, or a10-fold or more (e.g., 100-fold, 200-fold, 500-fold, 1×10³-fold,1×10⁴-fold, 1×10⁵-fold, 1×10⁶-fold, 1×10⁷-fold, etc.) when compared to asignificant signal (e.g., luminescent complex) under standard conditions(e.g., physiological conditions, assay conditions, etc.) and withtypical instrumentation (e.g., luminometer, etc.). In some embodiments,such non-luminescent peptides and polypeptides assemble, according tothe criteria described herein, to form a bioluminescent complex. As usedherein, a “non-luminescent element” is a non-luminescent peptide ornon-luminescent polypeptide.

As used herein, the term “interaction element” or “interaction molecule”refers to a moiety that assists in bringing together a pair ofnon-luminescent elements or a non-luminescent group to form abioluminescent complex. In a typical embodiment, a pair of interactionelements (a.k.a. “interaction pair”) is attached to a pair ofnon-luminescent elements (e.g., non-luminescent peptide/polypeptidepair), and the attractive interaction between the two interactionelements facilitates formation of the bioluminescent complex; althoughthe present invention is not limited to such a mechanism, and anunderstanding of the mechanism is not required to practice theinvention. Interaction elements may facilitate formation of thebioluminescent complex by any suitable mechanism (e.g., bringingnon-luminescent pair/group into close proximity, placing anon-luminescent pair/group in proper conformation for stableinteraction, reducing activation energy for complex formation,combinations thereof, etc.). An interaction element may be a protein,polypeptide, peptide, small molecule, cofactor, nucleic acid, lipid,carbohydrate, antibody, etc. An interaction pair may be made of two ofthe same interaction elements (i.e. homopair) or two differentinteraction elements (i.e. heteropair). In the case of a heteropair, theinteraction elements may be the same type of moiety (e.g., polypeptides)or may be two different types of moieties (e.g., polypeptide and smallmolecule). In some embodiments, in which complex formation by theinteraction pair is studied, an interaction pair may be referred to as a“target pair” or a “pair of interest,” and the individual interactionelements are referred to as “target elements” (e.g., “target peptide,”“target polypeptide,” etc.) or “elements of interest” (e.g., “peptide ofinterest,” “polypeptide or interest,” etc.).

As used herein, the terms “fusion”, “fusion polypeptide”, and “fusionprotein” refer to a chimeric protein containing a first protein orpolypeptide of interest (e.g., target sequence, etc.) joined to a seconddifferent peptide, polypeptide, or protein (e.g., detectable sequence,isolatable sequence, tag, etc.). The term “traditional fusion” refers toa fusion in which the first polypeptide or protein and the secondpeptide, polypeptide, or protein are fused end to end (e.g., C-terminusto N-terminus or N-terminus to C-terminus).

As used herein, the term “coelenterazine”, “coelenterazine substrate”,“coelenterazine derivative”, or “coelenterazine derivative substrate”refers to a class of reporter molecules that luminesce when acted uponby a wide variety of bioluminescent proteins such as luciferases (e.g.,marine luciferases). As used herein, the terms “coelenterazine”,“coelenterazine substrate”, “coelenterazine derivative”, or“coelenterazine derivative substrate” refer to naturally-occurring(“native”) coelenterazine. As used herein, the terms “a coelenterazine”,“a coelenterazine substrate”, “a coelenterazine derivative”, or “acoelenterazine derivative substrate” refers to native coelenterazine aswell as synthetic, e.g., derivative or variant, and natural analogsthereof, including furimazine, coelenterazine-n, coelenterazine-f,coelenterazine-h, coelenterazine-hcp, coelenterazine-cp,coelenterazine-c, coelenterazine-e, coelenterazine-fcp,bis-deoxycoelenterazine (“coelenterazine-hh”), coelenterazine-i,coelenterazine-icp, coelenterazine-v, and 2-methyl coelenterazine, inaddition to those disclosed in WO 2003/040100; U.S. application Ser. No.12/056,073 (paragraph [0086]); and U.S. Pat. No. 8,669,103; thedisclosures of which are incorporated by reference herein in theirentireties.

As used herein, the term “sample” is used in its broadest sense. In onesense, it is meant to include a specimen or culture obtained from anysource, as well as biological and environmental samples. Biologicalsamples may be obtained from animals (including humans) and encompassfluids, solids, tissues, and gases. Biological samples include bloodproducts, such as plasma, serum and the like. Sample may also refer tocell lysates or purified forms of the peptides and/or polypeptidesdescribed herein. Cell lysates may include cells that have been lysedwith a lysing agent or lysates such as rabbit reticulocyte or wheat germlysates. Sample may also include cell-free expression systems.Environmental samples include environmental material such as surfacematter, soil, water, crystals and industrial samples. Such examples arenot however to be construed as limiting the sample types applicable tothe present invention.

The term “energy acceptor” or “acceptor molecule” refers to any smallmolecule (e.g., chromophore), macromolecule (e.g., autofluorescentprotein, phycobiliproteins, nanoparticle, surface, etc.), or molecularcomplex that produces a readily detectable signal in response to energyabsorption (e.g., resonance energy transfer). In certain embodiments, anenergy acceptor is a fluorophore or other detectable chromophore.Suitable fluorophores include, but are not limited to: xanthenederivatives (e.g., fluorescein, rhodamine, Oregon green, eosin, Texasred, etc.), cyanine derivatives (e.g., cyanine, indocarbocyanine,oxacarbocyanine, thiacarbocyanine, merocyanine, etc.), naphthalenederivatives (e.g., dansyl and prodan derivatives), oxadiazolederivatives (e.g., pyridyloxazole, nitrobenzoxadiazole, benzoxadiazole,etc.), pyrene derivatives (e.g., cascade blue), oxazine derivatives(e.g., Nile red, Nile blue, cresyl violet, oxazine 170, etc.), acridinederivatives (e.g., proflavin, acridine orange, acridine yellow, etc.),arylmethine derivatives (e.g., auramine, crystal violet, malachitegreen, etc.), tetrapyrrole derivatives (e.g., porphin, phtalocyanine,bilirubin, etc.), CF dye (Biotium), BODIPY (Invitrogen), ALEXA FLuoR(Invitrogen), DYLIGHT FLUOR (Thermo Scientific, Pierce), ATTO and TRACY(Sigma Aldrich), FluoProbes (Interchim), DY and MEGASTOKES (Dyomics),SULFO CY dyes (CYANDYE, LLC), SETAU AND SQUARE DYES (SETA BioMedicals),QUASAR and CAL FLUOR dyes (Biosearch Technologies), SURELIGHT DYES (APC,RPE, PerCP, Phycobilisomes) (Columbia Biosciences), APC, APCXL, RPE, BPE(Phyco-Biotech), autofluorescent proteins (e.g., YFP, RFP, mCherry,mKate), quantum dot nanocrystals, etc. In some embodiments, afluorophore is a rhodamine analog (e.g., carboxy rhodamine analog). Incertain embodiments, energy acceptors include but are not limited tosmall molecule fluorescent dyes such as NCT, quenchers, fluorescentparticles such as Quantum dots, luminescent metal complexes, and anyother known energy acceptors.

The term “luminescent enzyme,” “bioluminescent enzyme,” or “luciferase”as used interchangeably herein refers to a class of oxidative enzymesused in bioluminescence wherein the enzyme produces and emits light whengiven a substrate. The luciferase may be a naturally occurring,recombinant, or mutant luciferase that uses a luciferase substrate. Theluciferase substrate may be luciferin, a luciferin derivative or analog,a pre-luciferin derivative or analog, a coelenterazine, or acoelenterazine derivative or analog. The luminescent enzyme, ifnaturally occurring, may be obtained easily by the skilled person froman organism. If the luminescent enzyme is one that occurs naturally oris a recombinant or mutant luminescent enzyme, e.g. one which retainsactivity in a luciferase-coelenterazine or luciferase-luciferin reactionof a naturally occurring luminescent enzyme, it can be obtained readilyfrom a culture of bacteria, yeast, mammalian cells, insect cells, plantcells, or the like, transformed to express a nucleic acid encoding theluminescent enzyme. Further, the recombinant or mutant luminescentenzyme can be derived from an in vitro cell-free system using a nucleicacid encoding the luciferase. Suitable luminescent enzymes includeluciferases derived from bioluminescent decapods, such as from theOplophoroidea (e.g. Oplophorus-derived luciferases), beetle luciferases(e.g., Photinus pyralis, Photuris pennsylvanica, etc.), marine organismssuch as cnidarians (e.g., Renilla luciferase), Aristeidae,Solenoceridae, Luciferidae, Sergestidae, Pasipheidae andThalassocarididae decapoda families, copepod luciferases, such asGaussia luciferase, such as Gaussia princeps luciferase, Metridialuciferases, such as Metridia longa and Metridia pacifica luciferases,Vargula luciferases, such as Vargula hilgendorfii luciferase,Pleuromamma xiphias luciferase, and photoproteins, such as Aequorin, andvariants, recombinants, and mutants thereof.

A “luminescent reaction mixture” contains materials that will allow theluminescent enzyme to generate a light signal, i.e., luminescence. Themixture may also contain the enzyme, e.g., the luciferase enzyme orluciferase. The materials, and the particular concentrations and/oramounts, needed to generate a luminescent signal will vary depending onthe luminescent enzyme used as well as the type of assay beingperformed. Often other materials will be added to the solutionincluding: a buffer to maintain the reaction at the proper pH, anadditive such as PRIONEX or Bovine serum albumin (BSA) to help maintainenzyme activity, reducing agents, detergents, etc.

As used herein, the terms “Oplophorus luciferase” and Oplophorus-derivedluciferase” are used interchangeably and refer to a luciferase secretedfrom the deep-sea shrimp Oplophorus gracilirostris (e.g., SEQ ID NO: 1),including wild-type, variants, and mutants thereof. For example,suitable Oplophorus luciferase variants are described in U.S. Pat. Nos.8,557,970 and 8,669,103, each of which is incorporated herein byreference in its entirety.

As used herein, the term “sequence identity” refers to the degree twopolymer sequences (e.g., peptide, polypeptide, nucleic acid, etc.) havethe same sequential composition of monomer subunits. The term “sequencesimilarity” refers to the degree with which two polymer sequences (e.g.,peptide, polypeptide, nucleic acid, etc.) have similar polymersequences. For example, similar amino acids are those that share thesame biophysical characteristics and can be grouped into the families,e.g., acidic (e.g., aspartate, glutamate), basic (e.g., lysine,arginine, histidine), non-polar (e.g., alanine, valine, leucine,isoleucine, proline, phenylalanine, methionine, tryptophan) anduncharged polar (e.g., glycine, asparagine, glutamine, cysteine, serine,threonine, tyrosine). The “percent sequence identity” (or “percentsequence similarity”) is calculated by: (1) comparing two optimallyaligned sequences over a window of comparison (e.g., the length of thelonger sequence, the length of the shorter sequence, a specifiedwindow), (2) determining the number of positions containing identical(or similar) monomers (e.g., same amino acids occurs in both sequences,similar amino acid occurs in both sequences) to yield the number ofmatched positions, (3) dividing the number of matched positions by thetotal number of positions in the comparison window (e.g., the length ofthe longer sequence, the length of the shorter sequence, a specifiedwindow), and (4) multiplying the result by 100 to yield the percentsequence identity or percent sequence similarity. For example, ifpeptides A and B are both 20 amino acids in length and have identicalamino acids at all but 1 position, then peptide A and peptide B have 95%sequence identity. If the amino acids at the non-identical positionshared the same biophysical characteristics (e.g., both were acidic),then peptide A and peptide B would have 100% sequence similarity. Asanother example, if peptide C is 20 amino acids in length and peptide Dis 15 amino acids in length, and 14 out of 15 amino acids in peptide Dare identical to those of a portion of peptide C, then peptides C and Dhave 70% sequence identity, but peptide D has 93.3% sequence identity toan optimal comparison window of peptide C. For the purpose ofcalculating “percent sequence identity” (or “percent sequencesimilarity”) herein, any gaps in aligned sequences are treated asmismatches at that position.

As used herein, the term “reporter moiety” may refer to a moiety that,under appropriate conditions, directly or indirectly generates adetectable signal. Exemplary reporter moieties include, but are notlimited to, fluorophores, luminescent molecules, dyes, radiolabels andsubstrates for enzymes such as luciferase. In some embodiments, areporter moiety may indirectly generate a detectable signal, forexample, when the reporter moiety is a substrate for an enzyme. Thereaction of the enzyme with the substrate then produces a detectablesignal such as fluorescence or luminescence. As used herein, the term“bioluminescent reporter moiety” may refer to a moiety that is asubstrate for a luciferase. For example, the bioluminescent reportermoiety can be a luciferin, a luciferin derivative, e.g., pre-luciferin,aminoluciferin, quionolyl-luciferin, napthyl luciferin, fluorolucifeirn,chloroluciferin, precursors of luciferin derivatives, a coelenterazineor a coelenterazine derivative or analog, e.g., furimazine. Theluminescent signal generated may be detected using a luminometer. Asused herein, the term “fluorescent reporter moiety” may refer to amoiety that fluoresces. For example, the fluorescent reporter moiety maybe a flurophore, such as coumarin, R110, fluoroscein, DDAO, resorufin,cresyl violet, sily xanthene, or carbopyronine. Fluorescence may bedetected using a fluorometer.

For the recitation of numeric ranges herein, each intervening numberthere between with the same degree of precision is explicitlycontemplated. For example, for the range of 6-9, the numbers 7 and 8 arecontemplated in addition to 6 and 9, and for the range 6.0-7.0, thenumber 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 areexplicitly contemplated.

2. Compounds

Provided herein are compounds that may selectively inhibit Oplophorusluciferase-derived bioluminescent complex, e.g., inhibit luciferaseactivity of the bioluminescent complex. In one aspect, disclosed arecompounds of formula (I), or salts thereof:

wherein:

R¹ is an aryl, a cycloalkyl, a heteroaryl, a heterocycle, an arylalkyl,a cycloalkylalkyl, a heteroarylalkyl, or a heterocyclylalkyl, whereinthe aryl, cycloalkyl, heteroaryl, and heterocycle are optionallysubstituted with one or more R^(W), wherein each R^(W) is independentlyselected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl,halogen, —CN, —OR^(A), —C₁₋₁₀alkylene-OR^(A), —CO—R^(A),—C₁₋₁₀alkylene-CO—R^(A), —CO—OR^(A), —C₁₋₁₀alkylene-CO—OR^(A),—CO—NHR^(A), —C₁₋₁₀alkylene-CO—NHR^(A), —NR^(B)R^(C),—C₁₋₁₀alkylene-NR^(B)R^(C), —NH—CO—C₁₋₄alkyl,—C₁₋₁₀alkylene-NH—CO—C₁₋₄alkyl, phenyl, and phenyl substituted with 1,2, 3, or 4 R^(D) groups;

each R² is independently C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, halogen, —CN,—OR^(A), —C₁₋₄alkylene-OR^(A), —CO—R^(A), —C₁₋₄alkylene-CO—R^(A),—CO—OR^(A), —C₁₋₄alkylene-CO—OR^(A), —CO—NHR^(A),—C₁₋₄alkylene-CO—NR^(A), —NR^(B)R^(C), —C₁₋₄alkylene-NR^(B)R^(C),—NH—CO—C₁₋₄alkyl, —C₁₋₄alkylene-NH—CO—C₁₋₄alkyl, phenyl, phenylsubstituted with 1, 2, 3, or 4 R^(D) groups, —C≡C—R^(A), or —C≡C—C₁4alkylene-OR^(A), or two R² together with the carbon atoms of the

moiety to which they are attached form a 5- or 6-membered fused ring;

each R³ is independently C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, halogen, —CN,—OR^(A), —C₁₋₄alkylene-OR^(A), —CO—R^(A), —CO—OR^(A), or —CO—NHR^(A), ortwo R³ together with the carbon atoms of the

moiety to which they are attached form a 5- or 6-membered fused ring;

R⁴ is H or C₁₋₄alkyl;

p is 0, 1, 2, 3, or 4;

q is 0, 1, 2, 3, or 4;

R^(A) at each occurrence is independently H, C₁₋₄alkyl, orC₁₋₄haloalkyl;

R^(B) and R^(C) at each occurrence are independently H or C₁₋₄alkyl, orR^(B) and R^(C) together with the N atom to which they are attached forma 5- or 6-membered heterocycle; and

R^(D) at each occurrence is independently C₁₋₄alkyl, —OC₁₋₄alkyl, —CN,or halogen.

In some embodiments, in compounds of formula (I):

R¹ is an aryl, a cycloalkyl, a heteroaryl, or a heterocycle, wherein thearyl, cycloalkyl, heteroaryl, and heterocycle are optionally substitutedwith one or more R^(W), wherein each R^(W) is independently selectedfrom the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, halogen, —CN,—OR^(A), —C₁₋₁₀alkylene-OR^(A), —CO—R^(A), —C₁₋₁₀alkylene-CO—R^(A),—CO—OR^(A), —C₁₋₁₀alkylene-CO—OR^(A), —CO—NHR^(A),—C₁₋₁₀alkylene-CO—NHR^(A), —NR^(B)R^(C), —C₁₋₁₀alkylene-NR^(B)R^(C),—NH—CO—C₁₋₄alkyl, —C₁₋₁₀alkylene-NH—CO—C₁₋₄alkyl, phenyl, and phenylsubstituted with 1, 2, 3, or 4 R^(D) groups;

each R² is independently C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, halogen, —CN,—OR^(A), —C₁₋₄alkylene-OR^(A), —CO—R^(A), —C₁₋₄alkylene-CO—R^(A),—CO—OR^(A), —C₁₋₄alkylene-CO—OR^(A), —CO—NHR^(A),C₁₋₄alkylene-CO—NR^(A), —NR^(B)R^(C), —C₁₋₄alkylene-NR^(B)R^(C),—NH—CO—C₁₋₄alkyl, —C₁₋₄alkylene-NH—CO—C₁₋₄alkyl, phenyl, phenylsubstituted with 1, 2, 3, or 4 R^(D) groups, —C≡C—R^(A), or—C≡C—C₁₋₄alkylene-OR^(A), or two R² together with the carbon atoms ofthe

moiety to which they are attached form a 5- or 6-membered fused ring;

each R³ is independently C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, halogen, —CN,—OR^(A), —C₁₋₄alkylene-OR^(A), —CO—R^(A), —CO—OR^(A), or —CO—NHR^(A), ortwo R³ together with the carbon atoms of the

moiety to which they are attached form a 5- or 6-membered fused ring;

R⁴ is H or C₁₋₄alkyl;

p is 0, 1, 2, 3, or 4;

q is 0, 1, 2, 3, or 4;

R^(A) at each occurrence is independently H, C₁₋₄alkyl, orC₁₋₄haloalkyl;

R^(B) and R^(C) at each occurrence are independently H or C₁₋₄alkyl, orR^(B) and R^(C) together with the N atom to which they are attached forma 5- or 6-membered heterocycle; and

R^(D) at each occurrence is independently C₁₋₄alkyl, —OC₁₋₄alkyl, —CN,or halogen.

In some embodiments, R¹ is an unsubstituted aryl, an unsubstitutedcycloalkyl, an unsubstituted heteroaryl, an unsubstituted heterocycle,or an unsubstituted arylalkyl.

In some embodiments, R¹ is an unsubstituted aryl, an unsubstitutedcycloalkyl, an unsubstituted heteroaryl, or an unsubstitutedheterocycle.

In some embodiments, R¹ is an aryl (such as a C₆₋₂₀aryl) or a heteroaryl(such as a 5- to 12-membered heteroaryl), wherein the aryl andheteroaryl are optionally substituted with one or more R^(W). In someembodiments, R¹ is a C₆₋₂₀aryl, wherein the aryl optionally substitutedwith one or more R^(W). In some embodiments, R¹ is a 5- to 12-memberedheteroaryl optionally substituted with one or more R^(W). In someembodiments, R¹ is a C₅₋₁₀cycloalkyl optionally substituted with one ormore R^(W). In some embodiments, R¹ is a 5- to 12-membered heterocycleoptionally substituted with one or more R^(W).

In some embodiments, R¹ is

each optionally substituted with one or more R^(W). In some embodiments,R¹ is

each of which is unsubstituted. In some embodiments, R¹ is

each of which is substituted with C₁₋₄alkyl or C₁₋₄haloalkyl.

In some embodiments, R¹ is

each of which is optionally substituted with one or more R^(W). In someembodiments, R¹ is

In some embodiments, each R^(W) is independently selected from the groupconsisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, halogen, or —CN. In someembodiments, R^(W) is —OR^(A), —C₁₋₄alkylene-OR^(A), —CO—R^(A),—C₁₋₄alkylene-CO—R^(A), —CO—OR^(A), —C₁₋₄alkylene-CO—OR^(A),—CO—NHR^(A), or —C₁₋₄alkylene-CO—NHR^(A). In some embodiments, R^(W) is—NR^(B)R^(C), —C₁₋₄alkylene-NR^(B)R^(C), —NH—CO—C₁₋₄alkyl, or—C₁₋₄alkylene-NH—CO—C₁₋₄alkyl. In some embodiments, R^(W) is phenyl orphenyl substituted with 1, 2, 3, or 4 R^(D) groups. In some embodiments,R^(W) is C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, halogen, or —CN. In someembodiments, R^(W) is C₁₋₄alkyl, such as methyl, ethyl, propyl, orbutyl.

In some embodiments, R^(W) is selected from the group consisting ofC₁₋₁₀alkyl, C₁₋₁₀haloalkyl, halogen, —CN, —OR^(A),—C₁₋₁₀alkylene-OR^(A), —CO—OR^(A), —C₁₋₁₀alkylene-CO—OR^(A), and phenyl.In some embodiments, each R^(A) is independently selected from hydrogen,methyl, and ethyl.

In some embodiments, R¹ is an arylalkyl (such as benzyl) that isoptionally substituted with one or more R^(W).

In some embodiments, R¹ is an aryl, a cycloalkyl, a heteroaryl, aheterocycle, or an arylalkyl, wherein the aryl, cycloalkyl, heteroaryl,and heterocycle are substituted with one R^(W), wherein R^(W) isselected from the group consisting of C₁₋₁₀alkyl, C₁₋₁₀haloalkyl,halogen, —CN, —OR^(A), —C₁₋₁₀alkylene-OR^(A), —CO—OR^(A),—C₁₋₁₀alkylene-CO—OR^(A), and phenyl, wherein each R^(A) isindependently selected from hydrogen, methyl, and ethyl.

In some embodiments, R¹ is

each of which is unsubstituted or substituted with one R^(W), whereinR^(W) is selected from the group consisting of C₁₋₁₀alkyl (e.g., methyl,ethyl, isopropyl, n-propyl, n-butyl, n-pentyl, n-hexyl, or n-octyl),C₁₋₁₀haloalkyl (e.g., —(CH₂)₄Br), halogen (e.g., fluoro, chloro, orbromo), —CN, —OR^(A) (e.g., —OCH₃), —C₁₋₁₀alkylene-OR^(A) (e.g.,—(CH₂)₄—OH or —(CH₂)₆—OH), —CO—OR^(A) (e.g., —COOH, —COOCH₃, or—COOCH₂CH₃), —C₁₋₁₀alkylene-CO—OR^(A) (e.g., —CH₂COOH, —CH₂COOCH₂CH₃,—(CH₂)₅—COOH, or —(CH₂)₅—COOCH₃), and phenyl.

In some embodiments, p is 0, 1, or 2. In some embodiments, p is 0. Insome embodiments, p is 1.

In some embodiments, R² is C₁₋₁₀alkyl, halogen, C₁₋₄haloalkyl, —OH,C₁₋₄alkylene-OH, —OC₁₋₄alkyl, —NH₂, phenyl, or —CO—OC₁₋₄alkyl. In someembodiments, R² is C₁₋₁₀alkyl. In some embodiments, R² is C₁₋₄alkyl,such as methyl, ethyl, propyl, or butyl. In some embodiments, R² ismethyl. In some embodiments, R² is halogen, C₁₋₄haloalkyl, —OH,C₁₋₄alkylene-OH, —OC₁₋₄alkyl, or —NH₂.

In some embodiments, R² is selected from C₁₋₁₀alkyl, C₁₋₁₀haloalkyl,halogen, —OR^(A), —C₁₋₄alkylene-OR^(A), —CO—R^(A), —CO—OR^(A),—C₁₋₄alkylene-CO—OR^(A), —CO—NHR^(A), —NR^(B)R^(C), —NH—CO—C₁₋₄alkyl,phenyl, and —C≡C—C₁₋₄alkylene-OR^(A), wherein each R^(A) isindependently selected from hydrogen, methyl, ethyl, andtrifluoromethyl.

In some embodiments, R² is selected from C₁₋₁₀alkyl (e.g., C₁₋₆alkyl,such as methyl, ethyl, isopropyl, n-propyl, n-butyl, n-pentyl, orn-hexyl), C₁₋₁₀haloalkyl (e.g., C₁₋₄haloalkyl, such as trifluoromethyl),halogen (e.g., fluoro, chloro, or bromo), —OR^(A) (e.g., —OH, —OCH₃,—O(CH₂)₃CH₃, or —OCF₃), —C₁₋₄alkylene-OR^(A) (e.g., —CH₂OH or—(CH₂)₃—OH), —CO—R^(A) (e.g., —COH), —CO—OR^(A) (e.g., —COOH or—COOCH₃), —C₁₋₄alkylene-CO—OR^(A) (e.g., —(CH₂)₂COOCH₃, —CO—NHR^(A)(e.g., —CONH(CH₂)₃CH₃, —NR^(B)R^(C) (e.g., —NH₂ or —NH(CH₂)₃CH₃,—NH—CO—C₁₋₄alkyl (e.g., —NH—CO—CH₃), phenyl, —C≡C—R^(A) (e.g.,—C≡C—(CH₂)₃CH₃) and —C≡C—C₁₋₄alkylene-OR^(A) (e.g., —C≡C—CH₂—OH). Insome embodiments, each R^(A) is independently selected from hydrogen,methyl, ethyl, n-propyl, and n-butyl.

In some embodiments, p is 2. In some embodiments, two R² together withthe carbon atoms of the

moiety to which they are attached form a 5- or 6-membered fused ring.For example, two R² together with the

moiety to which they are attached may form

In some embodiments, q is 0, 1, or 2. In some embodiments, q is 0. Insome embodiments, q is 1.

In some embodiments, R³ is selected from C₁₋₁₀alkyl, C₁₋₁₀haloalkyl,halogen, —CN, and —OR^(A), wherein R^(A) is selected from hydrogen andC₁₋₄alkyl. In some embodiments, R³ is selected from C₁₋₁₀alkyl (e.g.,C₁₋₄alkyl such as methyl, ethyl, isopropyl, n-propyl, or n-butyl),C₁₋₁₀haloalkyl (e.g., C₁₋₄haloalkyl such as trifluoromethyl), halogen(e.g., fluoro, chloro, or bromo), —CN, and —OR^(A) (e.g., —OH or —OCH₃).In some embodiments, R³ is C₁₋₄alkyl, halogen, —CN, —OH, or —OC₁₋₄alkyl.In some embodiments, R³ is halogen. In some embodiments, R² is C₁₋₄alkyl(such as methyl) and R³ is C₁₋₄alkyl, halogen, —CN, —OH, or —OC₁₋₄alkyl.

In some embodiments, q is 2. In some embodiments, two R³ together withthe carbon atoms of the

moiety to which they are attached form a 5- or 6-membered fused ring.For example, two R³ together with the

moiety to which they are attached may form

In some embodiments, p is 1 and q is 0. In some embodiments, p is 1 andq is 1. In some embodiments, R² is C₁₋₄alkyl (such as methyl), p is 1and q is 0. In some embodiments, R² is C₁₋₄alkyl (such as methyl), R³ isC₁₋₄alkyl, halogen, —CN, —OH, or —OC₁₋₄alkyl, p is 1, and q is 1. Insome embodiments, R² is methyl, R³ is —CH₃, halogen (such as F), —OCH₃,or —CN, p is 1, and q is 1.

In some embodiments, R⁴ is H. In some embodiments, R⁴ is C₁₋₄alkyl. Insome embodiments, R⁴ is ethyl.

R^(A) at each occurrence (as a substituent in R¹, R², or R³) isindependently H, C₁₋₄alkyl, or C₁₋₄haloalkyl. In some embodiments, R^(A)is H. In some embodiments, R^(A) is C₁₋₄alkyl. In some embodiments,R^(A) is methyl. In some embodiments, R^(A) is C₁₋₄haloalkyl, such as—CF₃.

R^(B) and R^(C) at each occurrence (as substituents in R¹ or R²) areindependently H or C₁₋₄alkyl, or R^(B) and R^(C) together with the Natom to which they are attached form a 5- or 6-membered heterocycle. Insome embodiments, R^(B) and R^(C) are both H. In some embodiments, R^(B)is H and R^(C) is C₁₋₄alkyl. In some embodiments, R^(B) is C₁₋₄alkyl andR^(C) is C₁₋₄alkyl. In some embodiments, R^(B) and R^(C) together withthe N atom to which they are attached form a 5- or 6-memberedheterocycle.

In some embodiments, R^(D) is C₁₋₄alkyl, such as methyl. In someembodiments, R^(D) is —OC₁₋₄alkyl, such as —OCH₃. In some embodiments,R^(D) is —CN or halogen.

In some embodiments, R¹ is

each of which is substituted with C₁₋₄alkyl or C₁₋₄haloalkyl, or R¹ is

R² is C₁₋₄alkyl, halogen, C₁₋₄haloalkyl, —OH, C₁₋₄alkylene-OH,—OC₁₋₄alkyl, or —NH₂, R³ is C₁₋₄alkyl, halogen, —CN, —OH, or—OC₁₋₄alkyl, p is 1, and q is 0 or 1.

In some embodiments, when p is 0, then R¹ is substituted with one ormore R^(W) (e.g., with one R^(W)). In some embodiments, when p is 0 andR¹ is phenyl, then R¹ is substituted with one or more R^(W) (e.g., withone R^(W)). In some embodiments, when R¹ is unsubstituted, then p is 1,2, 3, or 4 (e.g., p is 1 or 2, or p is 1). In some embodiments, when R¹is unsubstituted phenyl, then p is 1, 2, 3, or 4 (e.g., p is 1 or 2, orp is 1). In some embodiments, the compound is notN-phenyl-2-(phenylsulfonamido)benzamide.

In some embodiments, the compounds of formula (I) are compounds offormula (I-a), or salts thereof,

wherein

R¹ is a C₆₋₂₀aryl or a 5- to 12-membered heteroaryl, wherein the aryland heteroaryl are optionally substituted with one or more R^(W);

p is 0, 1, or 2;

q is 0 or 1;

R³ is C₁₋₄alkyl, halogen, —CN or —OR^(A);

R^(A) is H or C₁₋₄alkyl; and

R² and R^(W) are as defined herein.

In some embodiments, disclosed are compounds of formula (I-a), or saltsthereof, wherein R¹ is an unsubstituted C₆₋₂₀aryl or an unsubstituted 5-to 12-membered heteroaryl.

In some embodiments, disclosed are compounds of formula (I-a), or saltsthereof, wherein R¹ is

each optionally substituted with one or more R^(W). In some embodiments,R¹ of formula (I-a) is

In some embodiments, disclosed are compounds of formula (I-a), or saltsthereof, wherein R¹ is substituted with C₁₋₄alkyl or C₁₋₄haloalkyl. Forexample, R¹ of formula (I-a) may be

each substituted with C₁₋₄alkyl or C₁₋₄haloalkyl.

In some embodiments, disclosed are compounds of formula (I-a), or saltsthereof, wherein R¹ is

each of which is optionally substituted with one or more R^(W). In someembodiments, R¹ is

In some embodiments, disclosed are compounds of formula (I-a), or saltsthereof, wherein R¹ is

each of which is unsubstituted or substituted with one R^(W), whereinR^(W) is selected from the group consisting of C₁₋₁₀alkyl (e.g., methyl,ethyl, isopropyl, n-propyl, n-butyl, n-pentyl, n-hexyl, or n-octyl),C₁₋₁₀haloalkyl (e.g., —(CH₂)₄Br), halogen (e.g., fluoro, chloro, orbromo), —CN, —OR^(A) (e.g., —OCH₃), —C₁₋₁₀alkylene-OR^(A) (e.g.,—(CH₂)₄—OH or —(CH₂)₆—OH), —CO—OR^(A) (e.g., —COOH, —COOCH₃, or—COOCH₂CH₃), —C₁₋₁₀alkylene-CO—OR^(A) (e.g., —CH₂COOH, —CH₂COOCH₂CH₃,—(CH₂)₅—COOH, or —(CH₂)₅—COOCH₃), and phenyl.

In some embodiments, disclosed are compounds of formula (I-a), or saltsthereof, wherein R² is C₁₋₄alkyl (such as methyl, ethyl, propyl, orbutyl), halogen, C₁₋₄haloalkyl, —OH, C₁₋₄alkylene-OH, —OC₁₋₄alkyl, —NH₂,phenyl, or —CO—OC₁₋₄alkyl, or R² together with the carbon atoms of the

moiety to which they are attached form a 5- or 6-membered fused ring.For example, two R² of formula (I-a) together with the

moiety to which it is attached may form

In some embodiments, disclosed are compounds of formula (I-a), or saltsthereof, wherein R² is C₁₋₄alkyl (such as methyl). In some embodiments,disclosed are compounds of formula (I-a), or salts thereof, wherein R²is —OH, —C₁₋₄alkylene-OH (such as —CH₂OH), —OC₁₋₄alkyl (such as —OCH₃),or —NH₂. In some embodiments, disclosed are compounds of formula (I-a),or salts thereof, wherein p is 1 and q is 0. In some embodiments,disclosed are compounds of formula (I-a), or salts thereof, wherein R²is C₁₋₄alkyl (such as methyl), —OH, —C₁₋₄alkylene-OH (such as —CH₂OH),—OC₁₋₄alkyl (such as —OCH₃), or —NH₂, p is 1, and q is 0. In someembodiments, disclosed are compounds of formula (I-a), or salts thereof,wherein p is 1 and q is 1. In some embodiments, disclosed are compoundsof formula (I-a), or salts thereof, wherein R² is methyl, R³ is —CH₃,halogen (such as F), —OCH₃, or —CN, p is 1, and q is 1.

In some embodiments, disclosed are compounds of formula (I-a), or saltsthereof, wherein when p is 0 and R¹ is phenyl, then R¹ is substitutedwith one or more R^(W). In some embodiments, disclosed are compounds offormula (I-a), or salts thereof, wherein when R¹ is unsubstitutedphenyl, then p is 1, 2, 3, or 4 (e.g., p is 1 or 2, or p is 1). In someembodiments, disclosed are compounds of formula (I-a), or salts thereof,wherein when p is 0, then R¹ is substituted with one or more R^(W)(e.g., with one R^(W)). In some embodiments, disclosed are compounds offormula (I-a), or salts thereof, wherein when p is 0 and R¹ is phenyl,then R¹ is substituted with one or more R^(W) (e.g., with one R^(W)). Insome embodiments, disclosed are compounds of formula (I-a), or saltsthereof, wherein when R¹ is unsubstituted, then p is 1, 2, 3, or 4(e.g., p is 1 or 2, or p is 1). In some embodiments, disclosed arecompounds of formula (I-a), or salts thereof, wherein when R¹ isunsubstituted phenyl, then p is 1, 2, 3, or 4 (e.g., p is 1 or 2, or pis 1). In some embodiments, disclosed are compounds of formula (I-a), orsalts thereof, wherein the compound is notN-phenyl-2-(phenylsulfonamido)benzamide.

In some embodiments, the compounds of formula (I-a) are compounds offormula (I-a-1), or salts thereof,

wherein:

R¹ is

each optionally substituted with halogen, C₁₋₄alkyl, C₁₋₄haloalkyl, orphenyl; or R¹ is

R² is halogen, C₁₋₄alkyl, C₁₋₄haloalkyl, —OH, C₁₋₄alkylene-OH,—OC₁₋₄alkyl, or —NH₂; and

R³ and q are as defined in formula (I-a).

In some embodiments, disclosed are compounds of formula (I-a-1), orsalts thereof, wherein R¹ is

In some embodiments, disclosed are compounds of formula (I-a-1), orsalts thereof, wherein R¹ is

each of which is substituted with halogen, C₁₋₄alkyl, C₁₋₄haloalkyl, orphenyl. In some embodiments, disclosed are compounds of formula (I-a-1),or salts thereof, wherein R¹ is

In some embodiments, disclosed are compounds of formula (I-a-1), orsalts thereof, wherein R² is C₁₋₄alkyl (such as methyl), halogen (suchas Br), or C₁₋₄haloalkyl (such as —CF3). In some embodiments, disclosedare compounds of formula (I-a-1), or salts thereof, wherein R² isC₁₋₄alkyl (such as methyl). In some embodiments, disclosed are compoundsof formula (I-a-1), or salts thereof, wherein R² is —OH,—C₁₋₄alkylene-OH (such as —CH₂OH), —OC₁₋₄alkyl (such as —OCH₃), or —NH₂.In some embodiments, disclosed are compounds of formula (I-a-1), orsalts thereof, wherein R² is C₁₋₄alkyl (such as methyl), halogen (suchas Br), —OH, C₁₋₄alkylene-OH (such as —CH₂—OH), —OC₁₋₄alkyl (such as—OCH₃), or —NH₂, and q is 0. In some embodiments, disclosed arecompounds of formula (I-a-1), or salts thereof, wherein R² is C₁₋₄alkyl(such as methyl) and q is 0. In some embodiments, disclosed arecompounds of formula (I-a-1), or salts thereof, wherein R² is C₁₋₄alkyl(such as methyl), R³ is —CH₃, halogen (such as F), —OCH₃, or —CN, and qis 1.

Suitable compounds include the following:

-   N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(3-cyanothiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(2-cyanophenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   2-((4-methylphenyl)sulfonamido)-N-phenylbenzamide;-   N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-2-(phenylsulfonamido)benzamide;-   N-(benzo[b]thiophen-2-yl)-2-((4-formylphenyl)sulfonamido)benzamide;-   methyl    3-(4-(N-(2-(benzo[b]thiophen-2-ylcarbamoyl)phenyl)sulfamoyl)phenyl)propanoate;-   N-(benzo[b]thiophen-2-yl)-2-((3-methylphenyl)sulfonamido)benzamide;-   N-(benzo[b]thiophen-2-yl)-2-((4-(3-hydroxypropyl)phenyl)sulfonamido)benzamide;-   2-([1,1′-biphenyl]-3-sulfonamido)-N-(p-tolyl)benzamide;-   methyl 3-(N-(2-(p-tolylcarbamoyl)phenyl)sulfamoyl)benzoate;-   3-(N-(2-(p-tolylcarbamoyl)phenyl)sulfamoyl)benzoic acid;-   2-((3-acetamidophenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((3-aminophenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((3-(hydroxymethyl)phenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((3-(butylcarbamoyl)phenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((3-bromophenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((3-(butylamino)phenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((3-(hex-1-yn-1-yl)phenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((3-hexylphenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((3-(3-hydroxyprop-1-yn-1-yl)phenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((3-(3-hydroxypropyl)phenyl)sulfonamido)-N-(p-tolyl)benzamide;-   N-(p-tolyl)-2-((4-(trifluoromethyl)phenyl)sulfonamido)benzamide;-   2-((4-methoxyphenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((4-bromophenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-([1,1′-biphenyl]-4-sulfonamido)-N-(p-tolyl)benzamide;-   N-(p-tolyl)-2-((3-(trifluoromethyl)phenyl)sulfonamido)benzamide;-   N-(p-tolyl)-2-((3-(trifluoromethoxy)phenyl)sulfonamido)benzamide;-   N-(benzo[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-cyclohexyl-2-((4-methylphenyl)sulfonamido)benzamide;-   2-((4-methylphenyl)sulfonamido)-N-(naphthalen-2-yl)benzamide;-   2-((4-methylphenyl)sulfonamido)-N-(5,6,7,8-tetrahydronaphthalen-2-yl)benzamide;-   methyl    trans-4-(2-((4-methylphenyl)sulfonamido)benzamido)cyclohexane-1-carboxylate;-   trans-4-(2-((4-methylphenyl)sulfonamido)benzamido)cyclohexane-1-carboxylic    acid;-   2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide;-   ethyl 2-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)acetate;-   N-(3-isopropylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   ethyl 3-(2-((4-methylphenyl)sulfonamido)benzamido)benzoate;-   2-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)acetic acid;-   3-(2-((4-methylphenyl)sulfonamido)benzamido)benzoic acid;-   2-((4-methylphenyl)sulfonamido)-N-(m-tolyl)benzamide;-   N-(benzo[b]thiophen-2-yl)-3-((4-methylphenyl)sulfonamido)-2-naphthamide;-   2-((4-methylphenyl)sulfonamido)-N-(2-propylphenyl)benzamide;-   N-(benzo[b]thiophen-2-yl)-5-methyl-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(3-butylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(benzo[b]thiophen-2-yl)-5-cyano-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(4-butylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(benzo[b]thiophen-2-yl)-2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzamide;-   N-(4-hexylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   2-((4-methylphenyl)sulfonamido)-N-(4-octylphenyl)benzamide;-   methyl    6-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)hexanoate;-   6-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)hexanoic acid;-   N-(benzo[b]thiophen-2-yl)-2-((4-butylphenyl)sulfonamido)benzamide;-   N-(4-(6-hydroxyhexyl)phenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(benzo[b]thiophen-2-yl)-2-((4-pentylphenyl)sulfonamido)benzamide;-   N-(benzo[b]thiophen-2-yl)-5-butyl-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(4-(4-hydroxybutyl)phenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(4-(4-bromobutyl)phenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   5-methoxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide;-   N-(benzo[b]thiophen-2-yl)-5-methoxy-2-((4-methylphenyl)sulfonamido)benzamide;-   4-methoxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide;-   N-(benzo[b]thiophen-2-yl)-4-methoxy-2-((4-methylphenyl)sulfonamido)benzamide;-   2-((3-methoxyphenyl)sulfonamido)-N-(p-tolyl)benzamide;-   N-(benzo[b]thiophen-2-yl)-2-((3-methoxyphenyl)sulfonamido)benzamide;-   5-hydroxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((3-hydroxyphenyl)sulfonamido)-N-(p-tolyl)benzamide;-   2-((3-butoxyphenyl)sulfonamido)-N-(p-tolyl)benzamide;-   N-(2-bromophenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(3-bromophenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-([1,1′-biphenyl]-4-yl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(2-methoxyphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-([1,1′-biphenyl]-3-yl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(3-methoxyphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(4-methoxyphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;-   2-((N-ethyl-4-methylphenyl)sulfonamido)-N-(4-methoxyphenyl)benzamide;-   N-(benzo[b]thiophen-2-yl)-4-fluoro-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(benzo[b]thiophen-2-yl)-5-fluoro-2-((4-methylphenyl)sulfonamido)benzamide;-   N-benzyl-2-((4-methylphenyl)sulfonamido)benzamide;-   N-(4-methoxybenzyl)-2-((4-methylphenyl)sulfonamido)benzamide; and-   N-(benzo[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)-5-(trifluoromethyl)benzamide,

or a salt thereof.

(1) Salt Forms

A thienopyrrole compound described herein can be in the form of a salt.A neutral form of the compound may be regenerated by contacting the saltwith a base or acid and isolating the parent compound in a conventionalmanner. The parent form of the compound differs from the various saltforms in certain physical properties, such as solubility in polarsolvents, but otherwise the salts are equivalent to the parent form ofthe compound for the purposes of this disclosure.

For example, if the compound is anionic, or has a functional group whichmay be anionic (e.g., —COOH may be —COO⁻), then a salt may be formedwith a suitable cation. Examples of suitable inorganic cations include,but are not limited to, alkali metal ions such as Na⁺ and K⁺, alkalineearth cations such as Ca²⁺ and Mg²⁺, and other cations. Examples ofsuitable organic cations include, but are not limited to, ammonium ion(i.e., NH₄ ⁺) and substituted ammonium ions (e.g., NH₃R₁ ⁺, NH₂R₂ ⁺,NHR₃ ⁺, NR₄ ⁺). Examples of some suitable substituted ammonium ions arethose derived from: ethylamine, diethylamine, dicyclohexylamine,triethylamine, butylamine, ethylenediamine, ethanolamine,diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline,meglumine, and tromethamine, as well as amino acids, such as lysine andarginine.

If the compound is cationic, or has a functional group that may becationic (e.g., —NH₂ may be —NH₃ ⁺), then a salt may be formed with asuitable anion. Examples of suitable inorganic anions include, but arenot limited to, those derived from the following inorganic acids:hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric,nitrous, phosphoric, and phosphorous.

Examples of suitable organic anions include, but are not limited to,those derived from the following organic acids: 2-acetyoxybenzoic,acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric,edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucoheptonic,gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalenecarboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic,methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic,phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic,succinic, sulfanilic, tartaric, toluenesulfonic, and valeric. Examplesof suitable polymeric organic anions include, but are not limited to,those derived from the following polymeric acids: tannic acid,carboxymethyl cellulose.

Unless otherwise specified, a reference to a particular thienopyrrolecompound herein also includes salt forms thereof.

(2) Isomers

Certain thienopyrrole compounds may exist in one or more particulargeometric, optical, enantiomeric, diastereomeric, epimeric, atropic,stereoisomer, tautomeric, conformational, or anomeric forms, includingbut not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, andr-forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d-and 1-forms; (+) and (−) forms; keto-, enol-, and enolate-forms; syn-and anti-forms; synclinal- and anticlinal-forms; a- and β-forms; axialand equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referredto as “isomers” (or “isomeric forms”).

In some embodiments, a compound described herein may be anenantiomerically enriched isomer of a stereoisomer described herein. Forexample, the compound may have an enantiomeric excess of at least about10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%. Enantiomer, when used herein,refers to either of a pair of chemical compounds whose molecularstructures have a mirror-image relationship to each other.

In some embodiments, a preparation of a compound disclosed herein isenriched for an isomer of the compound having a selectedstereochemistry, e.g., R or S, corresponding to a selected stereocenter.For example, the compound has a purity corresponding to a compoundhaving a selected stereochemistry of a selected stereocenter of at leastabout 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.

In some embodiments, a composition described herein includes apreparation of a compound disclosed herein that is enriched for astructure or structures having a selected stereochemistry, e.g., R or S,at a selected stereocenter. Exemplary R/S configurations can be thoseprovided in an example described herein.

An “enriched preparation,” as used herein, is enriched for a selectedstereoconfiguration of one, two, three or more selected stereocenterswithin the subject compound. Exemplary selected stereocenters andexemplary stereoconfigurations thereof can be selected from thoseprovided herein, e.g., in an example described herein. By enriched ismeant at least 60%, e.g., of the molecules of compound in thepreparation have a selected stereochemistry of a selected stereocenter.In an embodiment it is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%,97%, 98%, or 99%. Enriched refers to the level of a subject molecule(s)and does not connote a process limitation unless specified.

The present compounds may be prepared in racemic form or as individualenantiomers or diastereomers by either stereospecific synthesis or byresolution. The compounds may, for example, be resolved into theircomponent enantiomers or diastereomers by standard techniques, such asthe formation of stereoisomeric pairs by salt formation with anoptically active base, followed by fractional crystallization andregeneration of the free acid. The compounds may also be resolved byformation of stereoisomeric esters or amides, followed bychromatographic separation and removal of the chiral auxiliary.Alternatively, the compounds may be resolved using a chiral HPLC column.The enantiomers also may be obtained from kinetic resolution of theracemate of corresponding esters using lipase enzymes.

Except as discussed below for tautomeric forms, specifically excludedfrom the term “isomers,” as used herein, are structural (orconstitutional) isomers (i.e., isomers which differ in the connectionsbetween atoms rather than merely by the position of atoms in space). Forexample, a reference to a methoxy group, —OCH₃, is not to be construedas a reference to its structural isomer, a hydroxymethyl group, —CH₂OH.Similarly, a reference to ortho-chlorophenyl is not to be construed as areference to its structural isomer, meta-chlorophenyl. However, areference to a class of structures may well include structurallyisomeric forms falling within that class (e.g., C₃-alkyl or propylincludes n-propyl and iso-propyl; C₄-alkyl or butyl includes n-, iso-,sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, andpara-methoxyphenyl).

The above exclusion does not pertain to tautomeric forms, for example,keto-, enol-, and enolate-forms, as in, for example, the followingtautomeric pairs: keto/enol, imine/enamine, amide/imino alcohol,amidine/amidine, nitroso/oxime, thioketone/enethiol,N-nitroso/hydroxyazo, and nitro/aci-nitro.

Note that specifically included in the term “isomer” are compounds withone or more isotopic substitutions. For example, H may be in anyisotopic form, including ¹H, ²H (D), and ³H (T); C may be in anyisotopic form, including ¹²C, ¹³C, and ¹⁴C; O may be in any isotopicform, including ¹⁶O and ¹⁸O; and the like.

3. Oplophorus Luciferase-Derived Bioluminescent Complexes

The disclosed compounds may be used to inhibit Oplophorusluciferase-derived bioluminescent complexes. The disclosed compounds mayinhibit the luciferase activity of the Oplophorus luciferase-derivedbioluminescent complexes. The Oplophorus luciferase may be a wild-typeOplophorus luciferase or a variant of an Oplophorus luciferase. TheOplophorus luciferase may be a variant of the luciferase of SEQ ID NO:7. Oplophorus luciferase variants are described in U.S. Pat. Nos.8,557,970 and 8,669,103, each of which is incorporated herein byreference in its entirety.

The Oplophorus luciferase-derived bioluminescent complex may be anassembly of two or more non-luminescent peptide and/or polypeptide units(e.g., non-luminescent pair). The Oplophorus luciferase-derivedbioluminescent complexes may include (a) a peptide comprising a peptideamino acid sequence having less than 100% sequence identity (e.g., >99%,<95%, <90%, <80%, <70%, <60%, <50%, etc.) greater than 40%(e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%)with SEQ ID NO: 2; and (b) a polypeptide comprising a polypeptide aminoacid sequence having less than 100% (e.g., >99%, <95%, <90%, <80%, <70%,<60%, <50%, etc.) and greater than 40%(e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%)sequence identity with SEQ ID NO: 3, wherein the bioluminescent complexexhibits detectable luminescence in the presence of a coelenterazinesubstrate. In certain embodiments, the present invention providesbioluminescent complexes comprising: (a) a peptide comprising a peptideamino acid sequence having SEQ ID NO: 4 or SEQ ID NO: 6; and (b) apolypeptide comprising a polypeptide amino acid sequence having SEQ IDNO: 5, wherein the bioluminescent complex exhibits detectableluminescence in the presence of a coelenterazine substrate. ExemplaryOplophorus luciferase-derived bioluminescent complexes include theNanoBiT® technology that includes a NanoBiT® SmBiT non-luminescentpeptide (SEQ ID NO: 6), NanoBiT® HiBiT non-luminescent peptide (SEQ IDNO: 4), and/or NanoBiT® LgBiT non-luminescent polypeptide (SEQ ID NO:5). Oplophorus luciferase-derived bioluminescent complexes are describedin U.S. Pat. Nos. 9,797,889 and 9,797,890, each of which is incorporatedherein by reference in its entirety.

4. Coelenterazine Substrates

The disclosed compounds of the present invention may be used to inhibitluciferase activity by competing or interfering with a coelenterazine orcoelenterazine-derivative substrate from binding to a luciferase.Coelenterazine substrates are a class of reporter molecules thatluminesce when acted upon by luciferases and other bioluminescentproteins. Examples of coelenterazine substrates include but are notlimited to: coelenterazine; coelenterazine derivatives and/or analogssuch as 2-furanylmethyl-deoxy-coelenterazine (furimazine),coelenterazine-n, coelenterazine-f, coelenterazine-h,coelenterazine-hcp, coelenterazine-cp, coelenterazine-c,coelenterazine-e, coelenterazine-fcp, bis-deoxycoelenterazine(“coelenterazine-hh”), coelenterazine-i, coelenterazine-icp,coelenterazine-v, and 2-methyl-coelenterazine, in addition to thosedisclosed in WO 2003/040100, U.S. Patent Publication No. 2008/0248511,and U.S. Patent Publication No. US 2012/0117667; pro-coelenterazines(i.e. compounds that are not substrates for a non-luminescent enzyme,which converts the compound to a substrate for a luciferase),quinone-masked coelenterazines, and the like. Further examples ofcoelenterazine substrates are described in, for example, U.S.Publication No. 2012/0107849, U.S. Publication No. 2013/0130289, U.S.patent application Ser. No. 14/608,910, and U.S. patent application Ser.No. 14/609,372, each of which is incorporated herein by reference.

5. Methods of Inhibiting Oplophorus Luciferase-Derived BioluminescentComplex Activity

The disclosed compounds may be used in methods to inhibit Oplophorusluciferase-derived bioluminescent complex, e.g., inhibit luciferaseactivity of the bioluminescent complex. The method may includecontacting a compound disclosed herein with a cell expressing orcontaining an Oplophorus luciferase-derived bioluminescent complex or anon-luminescent peptide and/or polypeptide of the Oplophorusluciferase-derived bioluminescent complex, wherein the disclosedcompounds may selectively inhibit the Oplophorus luciferase-derivedbioluminescent complex. The method may include contacting a compounddisclosed herein with a non-luminescent peptide and/or polypeptide of anOplophorus luciferase-derived bioluminescent complex, wherein thedisclosed compound inhibits the Oplophorus luciferase-derivedbioluminescent complex when the complex has been assembled. Thedisclosed compounds may be used in assays that are used detect thepresence or activity of enzymes using Oplophorus luciferase-derivedbioluminescent complexes to selectively inhibit the signal from theOplophorus luciferase-derived bioluminescent complexes. For example, thedisclosed compounds may be used in a bioluminogenic method which employsan Oplophorus luciferase-derived bioluminescent complex and acoelenterazine or coelenterazine-derivative substrate to detect one ormore molecules in a sample, e.g., a protein of interest (e.g., anenzyme, a binding partner, a ligand, etc.), a cofactor for an enzymaticreaction, an enzyme substrate, an enzyme inhibitor, an enzyme activator,or OH radicals, or one or more conditions, e.g., redox conditions. Whilethe coelenterazine substrate serves as a substrate for the Oplophorusluciferase-derived bioluminescent complex, the disclosed compounds mayserve to inhibit the luciferase-derived bioluminescent complex toselectively suppress the luminescent signal in embodiments in which suchsuppression may be desired, such as in applications involving temporalmultiplexing of multiple bioluminescent systems or in some plate-basedluminescent assays. For example, the disclosed compounds may be used toinhibit intracellular and/or extracellular Oplophorus luciferase-derivedbioluminescent complex activities.

(1) Protein Complementation Assays

In accordance with the above, the disclosed compounds may be used toinhibit an Oplophorus luciferase-derived bioluminescent complex whensuch a bioluminescent complex is used in other methods for detectingligand-protein and protein-protein interactions or proximity orco-localization such as the protein complementation assay (PCA) orenzyme fragmentation complementation (EFC) assay. PCA and EFC assaysprovide a means to detect the interaction of two interaction elements,e.g., biomolecules, polypeptides. PCA utilizes two fragments of the sameprotein, e.g., enzyme, that are fused to polypeptides of interest thatproduce light only when the two fragments of the same protein arebrought into close proximity with each other via the bindinginteractions of their fusion partners, e.g., polypeptides of interest,and reassembly into a functional, active protein, e.g., enzyme. Forexample, the NANOBIT® technology (Promega Corporation) may be used todetect molecular proximity by virtue of the reassembly of a luminescentenzyme via the binding interaction of enzyme units. The NanoBiT® systemmay comprise two or more non-luminescent peptide and/or polypeptideunits that may be expressed as a fusion with target molecule ofinterest. In some embodiments, the two units may comprise a NanoBiT®LgBiT non-luminescent polypeptide (NLpoly) and NanoBiT® SmBiTnon-luminescent peptide (NLpep). In some embodiments, the two units maycomprise a NanoBiT® LgBiT non-luminescent polypeptide (NLpoly) andNanoBiT® HiBiT non-luminescent peptide (NLpep). Oplophorusluciferase-derived bioluminescent complexes are described in U.S. Pat.Nos. 9,797,889 and 9,797,890, each of which is incorporated herein byreference in its entirety.

For example, an Oplophorus luciferase or Oplophorus luciferase variantcan be separated into two units, e.g., non-luminescent peptide orpolypeptide, e.g., at a site(s) tolerant to separation, and each unit,e.g., non-luminescent peptide or polypeptide, can be fused to one of apair of polypeptides of interest believed to interact, e.g., FKBP andFRB. If the two polypeptides of interest do interact, thenon-luminescent units, for example, then come into close proximity witheach other to reassembly into a bioluminescent complex. In someembodiments, the activity of the bioluminescent complex can then bedetected and measured. In some embodiments, the bioluminescent complexcan be used in a more general complementation system similar to lac-Z(Langley et al., PNAS 72:1254-1257 (1975)) or ribonuclease S (Levit andBerger, J. Biol. Chem. 251:1333-1339 (1976)). In some embodiments, aluminescent enzyme unit (designated “A”) known to complement withanother luminescent enzyme unit (“B”) can be fused to a target protein,and the resulting fusion can be monitored via luminescence in a cell orcell lysate containing fragment B. In some embodiments, the source ofunit B could be the same cell (e.g., if the gene for unit B isintegrated into the genome of the cell or is contained on anotherplasmid within the cell) or it could be a lysate or purified proteinderived from another cell. In some embodiments, this same fusion protein(unit A) could be captured or immobilized using a fusion between unit Band a polypeptide such as HaloTag capable of attachment to a solidsupport. In some embodiments, luminescence can be used to demonstratesuccessful capture or to quantify the amount of material captured.

(2) Molecule Detection Assays

In accordance with the above, the disclosed compounds may be used toinhibit an Oplophorus luciferase-derived bioluminescent complex whensuch a bioluminescent complex is used in other methods for detecting amolecule of interest. For example, NANOBIT® technology (PromegaCorporation) may be used to detect a molecule of interest. The NanoBiT®system may comprise two or more non-luminescent peptide and/orpolypeptide units. One or more of the non-luminescent peptide and/orpolypeptide units may be fused to the molecule of interest. The twounits may comprise a NanoBiT® LgBiT non-luminescent polypeptide (NLpoly)and NanoBiT® HiBiT non-luminescent peptide (NLpep). In some embodiments,the NanoBiT® HiBiT NLpep may be fused to the molecule of interest. Thesample comprising the NanoBiT® HiBiT NLpep fused to the molecule ofinterest may be contacted with the NanoBiT® LgBiT NLpoly. For example,the NanoBiT® LgBiT NLpoly may be added to a detection reagent containinga coelenterazine substrate. The resulting bioluminescence can bedetected and measured, and inhibited with a compound disclosed herein.In some embodiments, the NanoBiT® LgBiT NLpoly may be fused to themolecule of interest. The sample comprising the NanoBiT® LgBiT NLpolyfused to the molecule of interest may be contacted with the NanoBiT®HiBiT NLpep. For example, the NanoBiT® HiBiT NLpep may be added to adetection reagent containing a coelenterazine substrate.

(3) Use of Cell-Impermeable Compounds

In certain embodiments, the methods disclosed herein include contactinga sample (e.g., a cell) with a mixture of a cell-permeablecoelenterazine substrate and a compound described herein that ismodified such that it is cell-impermeable. In such embodiments, thedisclosed compounds and methods may be used to build up the initialbrightness of a high-throughput screening operation assay format andthen selectively inhibit any Oplophorus luciferase-derivedbioluminescent complex that may be excreted from cells to selectivelyinhibit luminescence that may occur outside of the cells. Such methodsmay provide for a more selective signal within cells.

(4) Use of Cell-Permeable Compounds

In certain embodiments, the methods disclosed herein include contactinga sample (e.g., a cell) with a mixture of a cell-permeablecoelenterazine substrate and a compound described herein that iscell-permeable. In such embodiments, the disclosed compounds can enterin to cells and selectively inhibit an Oplophorus luciferase-derivedbioluminescent complex therein. Such methods may be advantageous inmultiplexing assays that involve use of two or more luciferases and mayallow for inhibition of luminescence from an Oplophorusluciferase-derived bioluminescent complex so as to selectively viewluminescence from another luciferase inside the cell.

(5) Use with Transcriptional Reporters

The disclosed compounds may be used with genetic transcriptionalreporter systems. In certain embodiments, provided is a method formeasuring the activity of a promoter in a sample, wherein the promoteris operably linked to a gene encoding a non-luminescent unit, e.g.,non-luminescent polypeptide, of Oplophorus luciferase-derivedbioluminescent complex. The method includes (a) contacting the sample,which expresses a non-luminescent polypeptide of an Oplophorusluciferase-derived bioluminescent complex capable of forming abioluminescent complex with a non-luminescent peptide of Oplophorusluciferase-derived bioluminescent complex fused to a promoter, with acoelenterazine substrate and a non-luminescent peptide of an Oplophorusluciferase-derived bioluminescent complex capable of forming abioluminescent complex with a non-luminescent polypeptide of Oplophorusluciferase-derived bioluminescent complex; and (b) determining theactivity of the promoter by measuring luminescence of the sample. Themethod can further include a step of contacting the sample with acompound described herein to selectively inhibit the luminescencegenerated from the bioluminescent complex. The promoter may be operablylinked to the gene via a translational or transcriptional fusion. Abiological pathway of interest, for example, may be examined by treatinga cell that comprises the promoter, which is operably linked to a geneencoding a non-luminescent unit, e.g., non-luminescent polypeptide, ofthe Oplophorus luciferase-derived bioluminescent complex with an induceragent of the pathway. This promoter activity may then be measured andmonitored to study any correlation between the activity of the promoterand the pathway of interest, as well as obtain kinetic measurementsrelating to gene expression (e.g. inducibility, repression andactivation). The compound described herein can be used to selectivelyinhibit the luminescence from the Oplophorus luciferase-derivedbioluminescent complex.

(6) Multiplexing

The disclosed compounds may be used to inhibit Oplophorusluciferase-derived bioluminescent complexes as applied to temporalmultiplexing with other luciferases and assays. In some embodiments, theOplophorus luciferase-derived bioluminescent complex may be multiplexedwith another enzyme (e.g., a luciferase) that emits light at a differentwavelength, e.g., green firefly luciferase, e.g., Photinus pyralis(e.g., Luc2; Promega Corp) or red click beetle luciferase (CHROMA-LUC™luciferase; Promega Corp.). For example, if an Oplophorusluciferase-derived bioluminescent complex is used as a functionalreporter, then the green firefly luciferase or red CHROMA-LUC™luciferase could be used to control for non-specific effects on geneticregulation or to normalize for transfection efficiency. In someembodiments, luminescence generated from the Oplophorusluciferase-derived bioluminescent complex (approximately 460 nm) and redCHROMA-LUC (approximately 610 nm) can be easily resolved using aluminometer with wavelength-discriminating filters, enabling themeasurement of both signals from the same sample. In such embodiments, acompound described herein can be used to selectively inhibit theOplophorus luciferase-derived bioluminescent complex such that thesignal from the other luciferase can be selectively viewed.

In another example, an Oplophorus luciferase-derived bioluminescentcomplex could be used as a transcriptional reporter and paired with aluciferase that emits light at a different wavelength contained in anassay reagent. In another example, an Oplophorus luciferase-derivedbioluminescent complex may be used with one or more additionalluciferases, wherein the luminescence of each luciferase and thebioluminescent complex may be separately measured through the use ofselective enzyme inhibitors. For example, the luminescence of theOplophorus luciferase-derived bioluminescent complex may be measuredupon addition of appropriate substrates and buffers followed bymeasurement of a second luciferase upon a subsequent addition ofappropriate substrates and buffers and one or more compounds describedherein, which are selective for the an Oplophorus luciferase-derivedbioluminescent complex.

In some embodiments, the Oplophorus luciferase-derived bioluminescentcomplex thereof may be multiplexed with another enzyme (e.g. aluciferase) that emits light at the same wavelength. For example,NANOBIT® technology (Promega Corporation) may be multiplexed withNANOLUC. The NanoBiT® system may comprise two or more non-luminescentpeptide and/or polypeptide units. One or more of the non-luminescentpeptide and/or polypeptides units may be fused to a molecule ofinterest. In some embodiments, the NanoBiT® LgBiT non-luminescentpolypeptide and/or the NanoBiT® HiBiT non-luminescent peptide may befused to a molecule of interest. For example, the NanoBiT® LgBiTnon-luminescent polypeptide can be added to a detection reagentcontaining furimazine as a means to detect and quantitate a protein ofinterest that is fused to NanoBiT® HiBiT non-luminescent peptide. Asanother example, the NanoBiT® HiBiT non-luminescent peptide can be addedto a detection reagent containing furimazine as a means to detect andquantitate a protein of interest that is fused to NanoBiT® LgBiTnon-luminescent polypeptide. The disclosed compounds may be used toinhibit the luminescence of the resulting bioluminescent complex (e.g.,the HiBiT/LgBiT complex) without inhibiting luminescence from NanoLuc.

(7) Bioluminescence Resonance Energy Transfer (BRET)

The disclosed compounds may be used in any method in which an Oplophorusluciferase-derived bioluminescent complex is used for detectingligand-protein and/or protein-protein interactions. In variousembodiments, the Oplophorus luciferase-derived bioluminescent complexmay be used to transfer energy to an energy acceptor. One such method isBioluminescence Resonance Energy Transfer (BRET). With respect to BRET,energy transfer from a bioluminescent donor to a fluorescent acceptorresults in a shift in the spectral distribution of the emission oflight. This energy transfer may enable real-time monitoring ofprotein-protein or ligand-protein interaction in vitro or in vivo.

In some embodiments, the Oplophorus luciferase-derived bioluminescentcomplex used in BRET analysis can be used to determine if two moleculesare capable of binding to each other or co-localize in a cell. Forexample, an Oplophorus luciferase-derived bioluminescent complex can beused as a bioluminescence donor molecule, wherein one of thenon-luminescent units is combined with a molecule or protein of interestto create a first fusion protein. In some embodiments, thenon-luminescent peptide may be combined with a molecule or protein ofinterest to create a first fusion protein. In other embodiments, thenon-luminescent polypeptide may be combined with a molecule or proteinof interest to create a first fusion protein. In various embodiments,the first fusion proteins containing the non-luminescent unit, (e.g.,non-luminescent peptide or non-luminescent polypeptide) of an Oplophorusluciferase-derived bioluminescent complex can be used in BRET analysisto detect protein/protein interaction in systems including but notlimited to cell lysates, intact cells, and living animals. In variousembodiments, HALOTAG can be used as a fluorescent acceptor molecule. Insome embodiments, HALOTAG can be fused to a second protein of interestor to a complementing non-luminescent unit of the bioluminescent complex(e.g., non-luminescent polypeptide or non-luminescent peptide). Forexample, a non-luminescent polypeptide of an Oplophorusluciferase-derived bioluminescent complex can be fused to HALOTAG,expressed in cells or animals, and labeled with a fluorescent HALOTAG®ligand such as HALOTAG® TMR ligand. The fusion can subsequently beexcited to fluoresce in the presence of a cell-permeant luminescentenzyme substrate. As another example, a non-luminescent peptide of anOplophorus luciferase-derived bioluminescent complex can be fused toHaloTag, expressed in cells or animals, and labeled with a fluorescentHaloTag® ligand such as HaloTag® TMR ligand. The fusion can subsequentlybe excited to fluoresce in the presence of a cell-permeant luminescentenzyme substrate. In some embodiments, HALOTAG can be fused to a secondprotein of interest, and a complementing non-luminescent unit of theOplophorus luciferase-derived bioluminescent complex (e.g.,non-luminescent polypeptide or non-luminescent peptide) added via adetection reagent. In some embodiments, BRET may be performed using anOplophorus luciferase-derived bioluminescent complex in combination withfluorescent proteins including but not limited to Green FluorescentProtein (GFP) or Red Fluorescent Protein (RFP) or fluorescent labelsincluding fluorescein, rhodamine green, Oregon green, or Alexa 488, toname a few non-limiting examples.

In some embodiments, quenching the signal from Oplophorusluciferase-derived bioluminescent complex can improve the signal tobackground ratio when using a BRET-based plate assay.

In certain embodiments, a cell-permeable compound may be used to inhibitintracellular BRET. In certain embodiments, a cell-impermeable compoundmay be used to inhibit extracellular BRET. In certain embodiments, acell-impermeable compound may be used in a target engagement model.

6. Sample

The disclosed compounds may be used with samples containing biologicalcomponents. The sample may comprise cells. The sample may compriseheterogeneous mixtures of components (including intact cells, cellextracts, cell lysates, bacteria, viruses, organelles, exosomes, andmixtures thereof) or a single component or homogeneous group ofcomponents (e.g., natural or synthetic amino acid, nucleic acid orcarbohydrate polymers, or lipid membrane complexes). The disclosedcompounds may be generally non-toxic to living cells and otherbiological components within the concentrations of use.

The sample may include an animal (e.g., a vertebrate), a plant, afungus, physiological fluid (e.g., blood, plasma, urine, mucoussecretions and the like), a cell, a cell lysate, a cell supernatant, ora purified fraction of a cell (e.g., a subcellular fraction). In certainembodiments, the sample may be a cell. In some embodiments, the samplemay be a live cell. The cell may be a eukaryotic cell, e.g., yeast,avian, plant, insect or mammalian cells, including but not limited tohuman, simian, murine, canine, bovine, equine, feline, ovine, caprine orswine cells, or prokaryotic cells, or cells from two or more differentorganisms, or cell lysates or supernatants thereof. The cells may nothave been genetically modified via recombinant techniques(nonrecombinant cells), or may be recombinant cells which aretransiently transfected with recombinant DNA and/or the genome of whichis stably augmented with a recombinant DNA, or which genome has beenmodified to disrupt a gene, e.g., disrupt a promoter, intron or openreading frame, or replace one DNA fragment with another. The recombinantDNA or replacement DNA fragment may encode a molecule to be detected bythe methods of the invention, a moiety which alters the level oractivity of the molecule to be detected, and/or a gene product unrelatedto the molecule or moiety that alters the level or activity of themolecule. The cell may or may not express a luciferase. The cells mayhave been genetically modified via recombinant techniques.

7. Kits

Disclosed are kits for determining the presence or activity of anOplophorus luciferase-derived bioluminescent complex. The kit mayinclude one or more of the following: a compound or composition of theinvention that may inhibit the Oplophorus luciferase-derivedbioluminescent complex, a coelenterazine or coelenterazine-derivativesubstrate, and an Oplophorus luciferase-derived bioluminescent complex,e.g., polynucleotides for the expression of the non-luminescent peptidesand/or polypeptides of the Oplophorus luciferase-derived bioluminescentcomplex, instructions for carrying out a luminescence assay, andreaction buffer(s). The reaction buffers may be present in individualformulations for the non-luciferase enzyme reactions and the luminescentenzyme reactions or in a single formulation for a single step assay. Thereaction buffer may contain a non-luminescent unit of the Oplophorusluciferase-derived bioluminescent complex, e.g., non-luminescentpeptide. The kits may also contain other inhibitors, activators and/orenhancers for the non-luciferase enzyme(s). The kits may also contain apositive and/or negative control for the assay.

8. Examples Example 1 Syntheses of Compounds

General Procedure A: Sulfonamide Bond Formation.

To a solution of aniline derivative (1 eq) in pyridine was addedsubstituted benzenesulfonyl chloride (1.1 eq). The solution stirred atrt for 4-18 h. The mixture was diluted with dichloromethane and washedwith HCl (2 M). The organic layer was dried with sodium sulfate,filtered, concentrated, and purified with silica gel chromatography.

General Procedure B: Saponification.

To a solution of methyl or ethyl ester (1 eq) in dioxane, sodiumhydroxide (2 M, 2 eq) was added. The solution was stirred at 60° C. for2-18 h. The solution was acidified with HCl (2 M), diluted with ethylacetate and water, and the aqueous layer extracted with ethyl acetate.The organic layers were combined, dried with sodium sulfate, filtered,concentrated, and used as crude product in the next step.

General Procedure C1: Amide Bond Formation Via Acid Chloride.

To a solution of acid chloride derivative (1 eq) in dichloroethane wasadded pyridine (3-5 eq) and amine (1 eq). The reaction was stirred at rtfor 2-18 h. The mixture was diluted with DCM and washed with water andHCl (2 M). The organic layers were combined, dried with sodium sulfate,filtered, concentrated, and purified with silica gel chromatography.

General Procedure C2: Amide Bond Formation Via Carboxylate.

To a solution of carboxylic acid derivative (1 eq) in DMF was addedamine (1.2 eq), HBTU (2 eq), and diisopropylethylamine (3 eq). Thereaction was heated to 60-85° C. for 2-18 h. The mixture was dilutedwith ethyl acetate and washed with water and brine. The organic layerswere combined, dried with sodium sulfate, filtered, concentrated, andpurified with silica gel chromatography.

General Procedure D: Nitro Reduction.

To a solution of nitro derivative (1 eq) in ethyl acetate was added tinchloride hydrate (3-5 eq). The mixture was heated to reflux for 24-48 h.Saturated potassium carbonate was added and stirred at rt for 1 h. Thelayers were separated and the organic layer was washed with water, driedwith sodium sulfate, filtered, concentrated, and purified with silicagel chromatography.

Example compounds may be prepared according to the representativesynthesis methods of Scheme 1 or Scheme 2.

Example 2N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-0998)

Step 1.N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-2-nitrobenzamide(JRW-0994)

Following general procedure C1, 2-nitrobenzoyl chloride (113 mg, 0.61mmol) was reacted with2-amino-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carbonitrile (100 mg,0.61 mmol) to afford the desired product (160 mg, 84%) as a yellowsolid. ESI MS m/z 314 [M+H]⁺.

Step 2.2-amino-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)benzamide(JRW-0996)

Following general procedure D,N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-2-nitrobenzamide(160 mg, 0.51 mmol) was reacted with tin chloride hydrate (318 mg, 1.5mmol) to afford the desired product (80 mg, 55%) as a white solid. ESIMS m/z 284 [M+H]⁺.

Step 3.N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-0998)

Following general procedure A,2-amino-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)benzamide(80 mg, 0.28 mmol) was reacted with 4-methylbenzenesulfonyl chloride (54mg, 0.28 mmol) to afford the desired product (75 mg, 61%) as a lightyellow solid. ESI MS m/z 438 [M+H]⁺.

Example 3N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1004)

Step 1.N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2-nitrobenzamide(JRW-1000)

Following general procedure C1, 2-nitrobenzoyl chloride (187 mg, 1.0mmol) was reacted with2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (180 mg, 1.0mmol) to afford the desired product (290 mg, 87%) as a yellow solid. ESIMS m/z 328 [M+H]⁺.

Step 2.2-amino-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)benzamide(JRW-1002)

To a solution ofN-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2-nitrobenzamide(290 mg, 0.88 mmol) in ethanol/water (8/2 mL) was added ammoniumchloride (474 mg, 8.8 mmol) and iron dust (100 mg, 1.8 mmol). Thesuspension was heated to 60° C. for 18 h. The reaction was filtered andthe filtrate was added to celite, concentrated, and purified with silicagel chromatography to afford the desired product (57 mg, 21%) as a lightbrown solid. ESI MS m/z 298 [M+H]⁺.

Step 3.N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1004)

Following general procedure A,2-amino-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)benzamide (57mg, 0.19 mmol) was reacted with 4-methylbenzenesulfonyl chloride (36 mg,0.19 mmol) to afford the desired product (35 mg, 40%) as a white solid.ESI MS m/z 452 [M+H]⁺.

Example 4N-(3-cyanothiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1006)

Step 1. N-(3-cyanothiophen-2-yl)-2-nitrobenzamide (JRW-1001)

Following general procedure C1, 2-nitrobenzoyl chloride (171 mg, 0.93mmol) was reacted with 2-aminothiophene-3-carbonitrile (115 mg, 0.93mmol) to afford the desired product (190 mg, 75%) as a light brownsolid. ESI MS m/z 274 [M+H]⁺.

Step 2. 2-amino-N-(3-cyanothiophen-2-yl)benzamide (JRW-1003)

Following general procedure D, N-(3-cyanothiophen-2-yl)-2-nitrobenzamide(190 mg, 0.69 mmol) was reacted with tin chloride hydrate (433 mg, 2.1mmol) to afford the desired product (90 mg, 53%) as a light brown solid.ESI MS m/z 244 [M+H]⁺.

Step 3.N-(3-cyanothiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1006)

Following general procedure A, 2-amino-N-(3-cyanothiophen-2-yl)benzamide(90 mg, 0.37 mmol) was reacted with 4-methylbenzenesulfonyl chloride (85mg, 0.44 mmol) to afford the desired product (97 mg, 66%) as a lightbrown solid. ESI MS m/z 398 [M+H]⁺

Example 5 N-(2-cyanophenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1008)

Step 1. N-(2-cyanophenyl)-2-nitrobenzamide (JRW-1005)

Following general procedure C1, 2-nitrobenzoyl chloride (189 mg, 1.0mmol) was reacted with 2-aminobenzonitrile (120 mg, 1.0 mmol) to affordthe desired product (208 mg, 77%) as a white solid. ESI MS m/z 268[M+H]⁺.

Step 2. 2-amino-N-(2-cyanophenyl)benzamide (JRW-1007)

Following general procedure D, N-(2-cyanophenyl)-2-nitrobenzamide (200mg, 0.75 mmol) was reacted with tin chloride hydrate (466 mg, 2.2 mmol)to afford the desired product (80 mg, 45%) as a white solid. ESI MS m/z238 [M+H]⁺.

Step 3. N-(2-cyanophenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1008)

Following general procedure A, 2-amino-N-(2-cyanophenyl)benzamide (80mg, 0.34 mmol) was reacted with 4-methylbenzenesulfonyl chloride (128mg, 0.67 mmol) to afford the desired product (91 mg, 68%) as a whitesolid. ESI MS m/z 392 [M+H]⁺.

Example 6 2-((4-methylphenyl)sulfonamido)-N-phenylbenzamide (JRW-1011)

Step 1. 2-nitro-N-phenylbenzamide (JRW-1009)

Following general procedure C1, 2-nitrobenzoyl chloride (239 mg, 1.3mmol) was reacted with aniline (120 mg, 1.3 mmol) to afford crudeproduct (350 mg) as a white solid. ESI MS m/z 243 [M+H]⁺.

Step 2. 2-amino-N-phenylbenzamide (JRW-1010)

Following general procedure D, 2-nitro-N-phenylbenzamide (1.3 mmol) wasreacted with tin chloride hydrate (803 mg, 3.9 mmol) to afford thedesired product (200 mg, 73% over two steps) as a white solid. ESI MSm/z 213 [M+H]⁺.

Step 3. 2-((4-methylphenyl)sulfonamido)-N-phenylbenzamide (JRW-1011)

Following general procedure A, 2-amino-N-phenylbenzamide (200 mg, 0.94mmol) was reacted with 4-methylbenzenesulfonyl chloride (359 mg, 1.9mmol) to afford the desired product (340 mg, 98%) as a white solid. ESIMS m/z 367 [M+H]⁺.

Example 7N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-2-(phenylsulfonamido)benzamide(HL-0010)

Following general procedure A,2-amino-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)benzamide(40 mg, 0.14 mmol) was reacted with benzenesulfonyl chloride (30 mg,0.17 mmol) to afford the desired product (17 mg, 26%) as a light brownsolid. ESI MS m/z 424 [M+H]⁺.

Example 8N-(benzo[b]thiophen-2-yl)-2-((4-formylphenyl)sulfonamido)benzamide(HL-0038)

Step 1. N-(benzo[b]thiophen-2-yl)-2-nitrobenzamide (HL-0028)

Following general procedure C1, 2-nitrobenzoyl chloride (373 mg, 2.0mmol) was reacted with benzo[b]thiophen-2-amine (300 mg, 2.0 mmol) toafford desired product (50 mg, 8%) as a solid. ESI MS m/z 299 [M+H]⁺.

Step 2. 2-amino-N-(benzo[b]thiophen-2-yl)benzamide (HL-0036)

Following general procedure D,N-(benzo[b]thiophen-2-yl)-2-nitrobenzamide (100 mg, 0.33 mmol) wasreacted with tin chloride hydrate (209 mg, 1.0 mmol) to afford thedesired product (27 mg, 30%) as a solid. ESI MS m/z 269 [M+H]⁺.

Step 3.N-(benzo[b]thiophen-2-yl)-2-((4-formylphenyl)sulfonamido)benzamide(HL-0038)

Following general procedure A,2-amino-N-(benzo[b]thiophen-2-yl)benzamide (10 mg, 0.036 mmol) wasreacted with 4-formylbenzenesulfonyl chloride (7 mg, 0.037 mmol) toafford the desired product (5 mg, 31%) as a white solid. ESI MS m/z 437[M+H]⁺.

Example 9 methyl3-(4-(N-(2-(benzo[b]thiophen-2-ylcarbamoyl)phenyl)sulfamoyl)phenyl)propanoate(HL-0040)

Following general procedure A,2-amino-N-(benzo[b]thiophen-2-yl)benzamide (10 mg, 0.037 mmol) wasreacted with methyl 3-(4-(chlorosulfonyl)phenyl)propanoate (10 mg, 0.037mmol) to afford the desired product (12 mg, 63%) as a light brown solid.ESI MS m/z 495 [M+H]⁺.

Example 10N-(benzo[b]thiophen-2-yl)-2-((3-methylphenyl)sulfonamido)benzamide(HL-0041)

Following general procedure A,2-amino-N-(benzo[b]thiophen-2-yl)benzamide (10 mg, 0.032 mmol) wasreacted with 3-methylbenzenesulfonyl chloride (6 mg, 0.032 mmol) toafford the desired product (7 mg, 54%) as a white solid. ESI MS m/z 423[M+H]⁺.

Example 11N-(benzo[b]thiophen-2-yl)-2-((4-(3-hydroxypropyl)phenyl)sulfonamido)benzamide(HL-0062)

To a solution of methyl3-(4-(N-(2-(benzo[b]thiophen-2-ylcarbamoyl)phenyl)sulfamoyl)phenyl)propanoate(31 mg, 0.063 mmol) in DMF (2 mL) at 0° C. was added lithium borohydride(4 mg, 0.19 mmol). The reaction warmed to rt and stirred overnight. Themixture was diluted with ethyl acetate and water, and the aqueous layerextracted with ethyl acetate. The organic layers were combined, driedwith sodium sulfate, filtered, concentrated, and purified with silicagel chromatography to afford the desired product (17 mg, 60%) as a whitesolid. ESI MS m/z 467 [M+H]⁺.

Example 12 2-([1,1′-biphenyl]-3-sulfonamido)-N-(p-tolyl)benzamide(JRW-1248)

Step 1. 2-nitro-N-(p-tolyl)benzamide (JRW-1243)

Following general procedure C1, 2-nitrobenzoyl chloride (3.46 g, 18.6mmol) was reacted with p-toluidine (2.0 g, 18.6 mmol) to afford desiredproduct (4.6 g, 96%) as a light brown solid. ESI MS m/z 257 [M+H]⁺.

Step 2. 2-amino-N-(p-tolyl)benzamide (JRW-1247)

Following general procedure D, 2-nitro-N-(p-tolyl)benzamide (4.6 g, 18.0mmol) was reacted with tin chloride hydrate (11.2 mg, 54.0 mmol) toafford the desired product (3.3 g, 81%) as a white solid. ESI MS m/z 227[M+H]⁺.

Step 3. 2-([1,1′-biphenyl]-3-sulfonamido)-N-(p-tolyl)benzamide(JRW-1248)

Following general procedure A, 2-amino-N-(p-tolyl)benzamide (75 mg, 0.33mmol) was reacted with [1,1′-biphenyl]-3-sulfonyl chloride (92 mg, 0.36mmol) to afford the desired product (85 mg, 58%) as a white solid. ESIMS m/z 443 [M+H]⁺.

Example 13 methyl 3-(N-(2-(p-tolylcarbamoyl)phenyl)sulfamoyl)benzoate(JRW-1250)

Following general procedure A, 2-amino-N-(p-tolyl)benzamide (400 mg,1.78 mmol) was reacted with methyl 3-(chlorosulfonyl)benzoate (498 mg,2.1 mmol) to afford the desired product (670 mg, 89%) as a white foam.ESI MS m/z 425 [M+H]⁺.

Example 14 3-(N-(2-(p-tolylcarbamoyl)phenyl)sulfamoyl)benzoic acid(JRW-1251)

Following general procedure B, methyl3-(N-(2-(p-tolylcarbamoyl)phenyl)sulfamoyl)benzoate (650 mg, 1.5 mmol)was reacted with LiOH (110 mg, 4.6 mmol) to afford the desired product(580 mg, 92%) as a white solid. ESI MS m/z 411 [M+H]⁺.

Example 15 2-((3-acetamidophenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1253)

Following general procedure A, 2-amino-N-(p-tolyl)benzamide (400 mg,1.78 mmol) was reacted with 3-acetamidobenzenesulfonyl chloride (495 mg,2.1 mmol) to afford the desired product (690 mg, 92%) as a white foam.ESI MS m/z 424 [M+H]⁺.

Example 16 2-((3-aminophenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1255)

To a solution of 2-((3-acetamidophenyl)sulfonamido)-N-(p-tolyl)benzamide(690 mg, 1.6 mmol) in methanol (20 mL) was added sodium hydroxide (5 mL,2M). The mixture was heated to 85° C. for 5 h. The reaction was cooled,acidified to pH 5, diluted with DCM and water, and the aqueous layerextracted with DCM. The organic layers were combined, dried with sodiumsulfate, filtered, concentrated, and purified with silica gelchromatography to afford the desired product (62 mg, 10%) as a whitesolid. ESI MS m/z 382 [M+H]⁺.

Example 17 2-((3-(hydroxymethyl)phenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1261)

To a mixture of 3-(N-(2-(p-tolylcarbamoyl)phenyl)sulfamoyl)benzoic acid(54 mg, 0.13 mmol) in DCM (5 mL) was added HOBt (20 mg, 0.13 mmol) andEDC (25 mg, 0.13 mmol). The mixture stirred at rt for 30 min. Thesolution was concentrated to a white foam, after which the solid wasdissolved in THE (10 mL) and water (0.5 mL). The solution was cooled andsodium borohydride (10 mg, 0.26 mmol) was added. The reaction wasstirred at rt for 18 h, quenched with HCl, and diluted with ethylacetate and water. The organic layers were combined, dried with sodiumsulfate, filtered, concentrated, and purified with silica gelchromatography to afford the desired product (29 mg, 55%) as a whitesolid. ESI MS m/z 397 [M+H]⁺.

Example 182-((3-(butylcarbamoyl)phenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1263)

Following general procedure C2,3-(N-(2-(p-tolylcarbamoyl)phenyl)sulfamoyl)benzoic acid (50 mg, 0.12mmol) was reacted with butylamine (17 mg, 0.21 mmol) to afford desiredproduct (43 mg, 76%) as a white solid. ESI MS m/z 466 [M+H]⁺.

Example 19 2-((3-bromophenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1267)

Following general procedure A, 2-amino-N-(p-tolyl)benzamide (350 mg, 1.5mmol) was reacted with 3-bromobenzenesulfonyl chloride (474 mg, 1.8mmol) to afford the desired product (620 mg, 90%) as a light brownsolid. ESI MS m/z 446 [M+H]⁺.

Example 20 2-((3-(butylamino)phenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1269)

To a solution of 2-((3-aminophenyl)sulfonamido)-N-(p-tolyl)benzamide (50mg, 0.13 mmol) in THE (5 mL) was added butyraldehyde (14 mg, 0.20 mmol).The mixture was stirred at rt for 30 min after which sodiumtriacetoxyborohydride (55 mg, 0.26 mmol) was added. The reaction stirredfor at rt for 5 h, quenched with a saturated solution of NaHCO₃, anddiluted with ethyl acetate and water. The organic layers were combined,dried with sodium sulfate, filtered, concentrated, and purified withsilica gel chromatography to afford the desired product (27 mg, 47%) asa white solid. ESI MS m/z 438 [M+H]⁺.

Example 21 2-((3-(hex-1-yn-1-yl)phenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1270)

To a solution of 2-((3-bromophenyl)sulfonamido)-N-(p-tolyl)benzamide(100 mg, 0.22 mmol) in DMF (5 mL) was added 1-hexyne (36 mg, 0.45 mmol),triethylamine (68 mg, 0.67 mmol), triphenylphosphine (6 mg, 0.022 mmol),and PdCl₂(PPh₃)₂ (8 mg, 0.011 mmol). The suspension was purged withnitrogen. Copper iodide (4 mg, 0.022 mmol) was added and the reactionstirred at 60° C. for 18 h. The reaction was diluted with ethyl acetateand water, extracted with ethyl acetate, the organic layers werecombined, dried with sodium sulfate, filtered, concentrated, andpurified with silica gel chromatography to afford the desired product(50 mg, 50%) as an orange oil. ESI MS m/z 447 [M+H]⁺.

Example 22 2-((3-hexylphenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1271)

To a solution of2-((3-(hex-1-yn-1-yl)phenyl)sulfonamido)-N-(p-tolyl)benzamide (40 mg,0.090 mmol) in ethanol (10 mL) was added palladium on carbon (5 mg). Thereaction stirred at rt for 2 h with 40 psi hydrogen. The mixture wasfiltered through celite, concentrated, purified with silica gelchromatography to afford the desired product (25 mg, 62%) as a whitesolid. ESI MS m/z 451 [M+H]⁺.

Example 232-((3-(3-hydroxyprop-1-yn-1-yl)phenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1272)

To a solution of 2-((3-bromophenyl)sulfonamido)-N-(p-tolyl)benzamide(100 mg, 0.22 mmol) in DMF (5 mL) was added propargyl alcohol (25 mg,0.45 mmol), triethylamine (68 mg, 0.67 mmol), triphenylphosphine (6 mg,0.022 mmol), and PdCl₂(PPh₃)₂ (8 mg, 0.011 mmol). The suspension waspurged with nitrogen. Copper iodide (4 mg, 0.022 mmol) was added and thereaction stirred at 85° C. for 48 h. The reaction was diluted with ethylacetate and water, extracted with ethyl acetate, the organic layers werecombined, dried with sodium sulfate, filtered, concentrated, andpurified with silica gel chromatography to afford the desired product(30 mg, 31%) as a light yellow gum. ESI MS m/z 421 [M+H]⁺.

Example 242-((3-(3-hydroxypropyl)phenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1275)

To a solution of2-((3-(3-hydroxyprop-1-yn-1-yl)phenyl)sulfonamido)-N-(p-tolyl)benzamide(23 mg, 0.055 mmol) in ethanol (10 mL) was added palladium on carbon (5mg). The reaction stirred at rt for 1 h with 40 psi hydrogen. Themixture was filtered through celite, concentrated, purified with silicagel chromatography to afford the desired product (17 mg, 74%) as a whitesolid. ESI MS m/z 425 [M+H]⁺.

Example 25N-(p-tolyl)-2-((4-(trifluoromethyl)phenyl)sulfonamido)benzamide(JRW-1284)

Following general procedure A, 2-amino-N-(p-tolyl)benzamide (50 mg, 0.22mmol) was reacted with 4-(trifluoromethyl)benzenesulfonyl chloride (64mg, 0.26 mmol) to afford the desired product (86 mg, 89%) as a whitesolid. ESI MS m/z 434 [M+H]⁺.

Example 26 2-((4-methoxyphenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1285)

Following general procedure A, 2-amino-N-(p-tolyl)benzamide (50 mg, 0.22mmol) was reacted with 4-methoxybenzenesulfonyl chloride (55 mg, 0.26mmol) to afford the desired product (82 mg, 94%) as a white solid. ESIMS m/z 397 [M+H]⁺.

Example 27 2-((4-bromophenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1287)

Following general procedure A, 2-amino-N-(p-tolyl)benzamide (190 mg,0.84 mmol) was reacted with 4-bromobenzenesulfonyl chloride (257 mg, 1.0mmol) to afford the desired product (310 mg, 83%) as a white solid. ESIMS m/z 446 [M+H]⁺.

Example 28 2-([1,1′-biphenyl]-4-sulfonamido)-N-(p-tolyl)benzamide(JRW-1293)

To a solution of 2-((4-bromophenyl)sulfonamido)-N-(p-tolyl)benzamide(100 mg, 0.22 mmol) in dioxane (5 mL) was added phenylboronic acid (32mg, 0.27 mmol) and Pd(dppf)Cl₂ (18 mg, 0.022 mmol). The mixture waspurged with nitrogen after which aqueous Cs₂CO₃ (0.67 mL, 1 M) wasadded. The reaction was heated to 80° C. for 2 h. The mixture wasdiluted with ethyl acetate and washed with water and brine. The organiclayers were combined, dried with sodium sulfate, filtered, concentrated,and purified with silica gel chromatography to afford the desiredproduct (64 mg, 64%) as a white solid. ESI MS m/z 443 [M+H]⁺.

Example 29N-(p-tolyl)-2-((3-(trifluoromethyl)phenyl)sulfonamido)benzamide(JRW-1327)

Following general procedure A, 2-amino-N-(p-tolyl)benzamide (55 mg, 0.24mmol) was reacted with 3-(trifluoromethyl)benzenesulfonyl chloride (71mg, 0.29 mmol) to afford the desired product (13 mg, 12%) as a whitesolid. ESI MS m/z 435 [M+H]⁺.

Example 30N-(p-tolyl)-2-((3-(trifluoromethoxy)phenyl)sulfonamido)benzamide(JRW-1328)

Following general procedure A, 2-amino-N-(p-tolyl)benzamide (55 mg, 0.24mmol) was reacted with 3-(trifluoromethoxy)benzenesulfonyl chloride (76mg, 0.29 mmol) to afford the desired product (42 mg, 38%) as a whitesolid. ESI MS m/z 451 [M+H]⁺.

Example 31N-(benzo[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide(HL-0005)

Step 1. methyl 2-((4-methylphenyl)sulfonamido)benzoate (HL-0001)

Following general procedure A, methyl 2-aminobenzoate (1.0 g, 6.6 mmol)was reacted with 4-methylbenzenesulfonyl chloride (1.5 g, 7.9 mmol) toafford the desired product (1.25 g, 62%) as a white solid. ESI MS m/z306 [M+H]⁺.

Step 2. 2-((4-methylphenyl)sulfonamido)benzoic acid (HL-0003)

Following general procedure B, methyl2-((4-methylphenyl)sulfonamido)benzoate (1.2 g, 4.1 mmol) was reactedwith LiOH (294 mg, 12.3 mmol) to afford the desired product (1.0 g, 86%)as a white solid. ESI MS m/z 292 [M+H]⁺.

Step 3.N-(benzo[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide(HL-0005)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with benzo[b]thiophen-2-amine (31mg, 0.21 mmol) to afford desired product (44 mg, 96%) as a brown solid.ESI MS m/z 423 [M+H]⁺.

Example 32 N-cyclohexyl-2-((4-methylphenyl)sulfonamido)benzamide(HL-0006)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with cyclohexylamine (20 mg, 0.21mmol) to afford desired product (14 mg, 22%) as a light yellow solid.ESI MS m/z 373 [M+H]⁺.

Example 33 2-((4-methylphenyl)sulfonamido)-N-(naphthalen-2-yl)benzamide(HL-0007)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with naphthalen-2-amine (29 mg, 0.21mmol) to afford desired product (40 mg, 54%) as a light brown solid. ESIMS m/z 417 [M+H]⁺.

Example 342-((4-methylphenyl)sulfonamido)-N-(5,6,7,8-tetrahydronaphthalen-2-yl)benzamide(HL-0008)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with5,6,7,8-tetrahydronaphthalen-2-amine (30 mg, 0.21 mmol) to afforddesired product (33 mg, 44%) as a white solid. ESI MS m/z 421 [M+H]⁺.

Example 35 methyltrans-4-(2-((4-methylphenyl)sulfonamido)benzamido)cyclohexane-1-carboxylate(HL-0009)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with methyltrans-4-aminocyclohexane-1-carboxylate HCl (40 mg, 0.21 mmol) to afforddesired product (41 mg, 55%) as a solid. ESI MS m/z 431 [M+H]⁺.

Example 36trans-4-(2-((4-methylphenyl)sulfonamido)benzamido)cyclohexane-1-carboxylicacid (HL-0012)

Following general procedure B, methyltrans-4-(2-((4-methylphenyl)sulfonamido)benzamido)cyclohexane-1-carboxylate(33 mg, 0.077 mmol) was reacted with LiOH (4 mg, 0.16 mmol) to affordthe desired product (29 mg, 84%) as a light brown solid. ESI MS m/z 417[M+H]⁺.

Example 37 2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide(HL-0019)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with 4-methyl-aniline (22 mg, 0.21mmol) to afford desired product (34 mg, 52%) as a light brown solid. ESIMS m/z 381 [M+H]⁺.

Example 38 ethyl2-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)acetate (HL-0023)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with ethyl 2-(4-aminophenyl)acetate(37 mg, 0.21 mmol) to afford desired product (32 mg, 42%) as a solid.ESI MS m/z 453 [M+H]⁺.

Example 39N-(3-isopropylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide (HL-0025)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with 3-isopropylaniline (28 mg, 0.21mmol) to afford desired product (49 mg, 71%) as a white solid. ESI MSm/z 409 [M+H]⁺.

Example 40 ethyl 3-(2-((4-methylphenyl)sulfonamido)benzamido)benzoate(HL-0026)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with ethyl 3-aminobenzoate (34 mg,0.21 mmol) to afford desired product (50 mg, 67%) as a solid. ESI MS m/z439 [M+H]⁺.

Example 41 2-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)aceticacid (HL-0030)

Following general procedure B, ethyl2-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)acetate (23 mg,0.052 mmol) was reacted with LiOH (3 mg, 0.11 mmol) to afford thedesired product (17 mg, 79%) as a brown solid. ESI MS m/z 425 [M+H]⁺.

Example 42 3-(2-((4-methylphenyl)sulfonamido)benzamido)benzoic acid(HL-0031)

Following general procedure B, ethyl3-(2-((4-methylphenyl)sulfonamido)benzamido)benzoate (23 mg, 0.054 mmol)was reacted with LiOH (3 mg, 0.11 mmol) to afford the desired product(12 mg, 54%) as a light yellow solid. ESI MS m/z 411 [M+H]⁺.

Example 43 2-((4-methylphenyl)sulfonamido)-N-(m-tolyl)benzamide(HL-0044)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with m-toluidine (22 mg, 0.21 mmol)to afford desired product (57 mg, 87%) as a white solid. ESI MS m/z 381[M+H]⁺.

Example 44N-(benzo[b]thiophen-2-yl)-3-((4-methylphenyl)sulfonamido)-2-naphthamide(HL-0057)

Step 1. methyl 3-((4-methylphenyl)sulfonamido)-2-naphthoate (HL-0049)

Following general procedure A, methyl 3-amino-2-naphthoate (300 mg, 1.5mmol) was reacted with 4-methylbenzenesulfonyl chloride (341 mg, 1.8mmol) to afford the desired product (340 mg, 64%) as a solid. ESI MS m/z356 [M+H]+.

Step 2. 3-((4-methylphenyl)sulfonamido)-2-naphthoic acid (HL-0052)

Following general procedure B, methyl3-((4-methylphenyl)sulfonamido)-2-naphthoate (340 mg, 0.96 mmol) wasreacted with LiOH (69 mg, 2.9 mmol) to afford the desired product (231mg, 71%) as a solid. ESI MS m/z 342 [M+H]⁺.

Step 3.N-(benzo[b]thiophen-2-yl)-3-((4-methylphenyl)sulfonamido)-2-naphthamide(HL-0057)

Following general procedure C2,3-((4-methylphenyl)sulfonamido)-2-naphthoic acid (50 mg, 0.15 mmol) wasreacted with benzo[b]thiophen-2-amine (22 mg, 0.15 mmol) to afforddesired product (28 mg, 40%) as a light brown solid. ESI MS m/z 473[M+H]⁺.

Example 45 2-((4-methylphenyl)sulfonamido)-N-(2-propylphenyl)benzamide(HL-0059)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with 2-propylaniline (23 mg, 0.17mmol) to afford desired product (28 mg, 40%) as a white solid. ESI MSm/z 409 [M+H]⁺.

Example 46N-(benzo[b]thiophen-2-yl)-5-methyl-2-((4-methylphenyl)sulfonamido)benzamide(HL-0061)

Step 1. ethyl 5-methyl-2-((4-methylphenyl)sulfonamido)benzoate (HL-0053)

Following general procedure A, ethyl 2-amino-5-methylbenzoate (300 mg,1.7 mmol) was reacted with 4-methylbenzenesulfonyl chloride (638 mg, 3.4mmol) to afford the desired product (404 mg, 72%) as a solid. ESI MS m/z334 [M+H]⁺.

Step 2. 5-methyl-2-((4-methylphenyl)sulfonamido)benzoic acid (HL-0058)

Following general procedure B, ethyl5-methyl-2-((4-methylphenyl)sulfonamido)benzoate (404 mg, 1.2 mmol) wasreacted with LiOH (87 mg, 3.6 mmol) to afford the desired product (262mg, 71%) as a solid. ESI MS m/z 306 [M+H]⁺.

Step 3.N-(benzo[b]thiophen-2-yl)-5-methyl-2-((4-methylphenyl)sulfonamido)benzamide(HL-0061)

Following general procedure C2,5-methyl-2-((4-methylphenyl)sulfonamido)benzoic acid (50 mg, 0.16 mmol)was reacted with benzo[b]thiophen-2-amine (24 mg, 0.16 mmol) to afforddesired product (68 mg, 95%) as a light yellow solid. ESI MS m/z 437[M+H]⁺.

Example 47 N-(3-butylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide(HL-0070)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with 3-butylaniline (25 mg, 0.17mmol) to afford desired product (18 mg, 25%) as a white solid. ESI MSm/z 423 [M+H]⁺.

Example 48N-(benzo[b]thiophen-2-yl)-5-cyano-2-((4-methylphenyl)sulfonamido)benzamide(HL-0071)

Step 1. methyl 5-cyano-2-((4-methylphenyl)sulfonamido)benzoate (HL-0056)

Following general procedure A, methyl 2-amino-5-cyanobenzoate (300 mg,1.7 mmol) was reacted with 4-methylbenzenesulfonyl chloride (649 mg, 3.4mmol) to afford the desired product (360 mg, 64%) as a solid. ESI MS m/z331 [M+H]⁺.

Step 2. 5-cyano-2-((4-methylphenyl)sulfonamido)benzoic acid (HL-0060)

Following general procedure B, methyl5-cyano-2-((4-methylphenyl)sulfonamido)benzoate (360 mg, 1.1 mmol) wasreacted with LiOH (78 mg, 3.3 mmol) to afford the desired product (140mg, 41%) as a solid. ESI MS m/z 317 [M+H]⁺.

Step 3.N-(benzo[b]thiophen-2-yl)-5-cyano-2-((4-methylphenyl)sulfonamido)benzamide(HL-0071)

Following general procedure C2,5-cyano-2-((4-methylphenyl)sulfonamido)benzoic acid (92 mg, 0.29 mmol)was reacted with benzo[b]thiophen-2-amine (43 mg, 0.29 mmol) to afforddesired product (47 mg, 36%) as a light brown solid. ESI MS m/z 448[M+H]⁺.

Example 49 N-(4-butylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1076)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (55 mg, 0.19 mmol) was reacted with 4-butylaniline (42 mg, 0.28mmol) to afford desired product (68 mg, 86%) as a light brown oil. ESIMS m/z 423 [M+H]⁺.

Example 50N-(benzo[b]thiophen-2-yl)-2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzamide(JRW-1077)

Step 1. methyl 2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzoate(HL-0068)

Following general procedure A, methyl 2-aminobenzoate (200 mg, 1.7 mmol)was reacted with 5,6,7,8-tetrahydronaphthalene-2-sulfonyl chloride (366mg, 1.6 mmol) to afford the desired product (289 mg, 63%) as a solid.ESI MS m/z 346 [M+H]⁺.

Step 2. 2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzoic acid(HL-0072)

Following general procedure B, methyl2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzoate (289 mg, 0.84mmol) was reacted with LiOH (60 mg, 2.5 mmol) to afford the desiredproduct (264 mg, 95%) as a solid. ESI MS m/z 332 [M+H]⁺.

Step 3.N-(benzo[b]thiophen-2-yl)-2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzamide(JRW-1077)

Following general procedure C2,2-((5,6,7,8-tetrahydronaphthalene)-2-sulfonamido)benzoic acid (50 mg,0.15 mmol) was reacted with benzo[b]thiophen-2-amine (27 mg, 0.18 mmol)to afford desired product (18 mg, 26%) as a brown oil. ESI MS m/z 463[M+H]⁺.

Example 51 N-(4-hexylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1090)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with 4-hexylaniline (36 mg, 0.21mmol) to afford desired product (61 mg, 79%) as a white solid. ESI MSm/z 451 [M+H]⁺.

Example 52 2-((4-methylphenyl)sulfonamido)-N-(4-octylphenyl)benzamide(JRW-1091)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with 4-octylaniline (42 mg, 0.21mmol) to afford desired product (67 mg, 81%) as a white solid. ESI MSm/z 479 [M+H]⁺.

Example 53 methyl6-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)hexanoate(JRW-1107)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with methyl6-(4-aminophenyl)hexanoate (45 mg, 0.21 mmol) to afford desired product(65 mg, 76%) as an orange oil. ESI MS m/z 479 [M+H]⁺.

Example 546-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)hexanoic acid(JRW-1110)

Following general procedure B, methyl6-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)hexanoate (55 mg,0.11 mmol) was reacted with LiOH (8 mg, 0.33 mmol) to afford the desiredproduct (50 mg, 94%) as a light brown solid. ESI MS m/z 481 [M+H]⁺.

Example 55N-(benzo[b]thiophen-2-yl)-2-((4-butylphenyl)sulfonamido)benzamide(JRW-1114)

Step 1. methyl 2-((4-butylphenyl)sulfonamido)benzoate (JRW-1111)

Following general procedure A, methyl 2-aminobenzoate (1.0 g, 6.6 mmol)was reacted with 4-butylbenzenesulfonyl chloride (1.7 g, 7.3 mmol) toafford crude product as a light brown oil. ESI MS m/z 348 [M+H]⁺.

Step 2. 2-((4-butylphenyl)sulfonamido)benzoic acid (JRW-1112)

Step 3.N-(benzo[b]thiophen-2-yl)-2-((4-butylphenyl)sulfonamido)benzamide(JRW-1114)

Following general procedure C2, 2-((4-butylphenyl)sulfonamido)benzoicacid (120 mg, 0.36 mmol) was reacted with benzo[b]thiophen-2-amine (54mg, 0.36 mmol) to afford desired product (25 mg, 15%) as an off whitesolid. ESI MS m/z 465 [M+H]⁺.

Example 56N-(4-(6-hydroxyhexyl)phenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1120)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (150 mg, 0.51 mmol) was reacted with 6-(4-aminophenyl)hexan-1-ol(100 mg, 0.51 mmol) to afford desired product (60 mg, 25%) as a whitefoam. ESI MS m/z 467 [M+H]⁺.

Example 57N-(benzo[b]thiophen-2-yl)-2-((4-pentylphenyl)sulfonamido)benzamide(JRW-1121)

Step 1. methyl 2-((4-pentylphenyl)sulfonamido)benzoate (JRW-1115)

Following general procedure A, methyl 2-aminobenzoate (1.0 g, 6.6 mmol)was reacted with 4-pentylbenzenesulfonyl chloride (1.8 g, 7.3 mmol) toafford crude product (2.3 g) as an orange oil. ESI MS m/z 362 [M+H]⁺.

Step 2. 2-((4-pentylphenyl)sulfonamido)benzoic acid (JRW-1116)

Following general procedure B, methyl2-((4-pentylphenyl)sulfonamido)benzoate (2.3 g, 6.4 mmol) was reactedwith NaOH (6.4 mL, 2M, 12.7 mmol) to afford crude product (2.2 g) as alight pink solid. ESI MS m/z 348 [M+H]⁺.

Step 3.N-(benzo[b]thiophen-2-yl)-2-((4-pentylphenyl)sulfonamido)benzamide(JRW-1121)

Following general procedure C2, 2-((4-pentylphenyl)sulfonamido)benzoicacid (100 mg, 0.29 mmol) was reacted with benzo[b]thiophen-2-amine (34mg, 0.23 mmol) to afford desired product (57 mg, 41%) as an orange foam.ESI MS m/z 479 [M+H]⁺.

Example 58N-(benzo[b]thiophen-2-yl)-5-butyl-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1146)

Step 1. 5-butyl-2-((4-methylphenyl)sulfonamido)benzoic acid (JRW-1142)

Following general procedure A, 2-amino-5-butylbenzoic acid (220 mg, 1.1mmol) was reacted with 4-methylbenzenesulfonyl chloride (325 mg, 1.7mmol) to afford desired product (275 mg, 69%) as a brown solid. ESI MSm/z 348 [M+H]⁺.

Step 2.N-(benzo[b]thiophen-2-yl)-5-butyl-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1146)

Following general procedure C2,5-butyl-2-((4-methylphenyl)sulfonamido)benzoic acid (275 mg, 0.79 mmol)was reacted with benzo[b]thiophen-2-amine (118 mg, 0.79 mmol) to afforddesired product (30 mg, 8%) as a brown solid. ESI MS m/z 479 [M+H]⁺.

Example 59N-(4-(4-hydroxybutyl)phenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1150)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (250 mg, 0.86 mmol) was reacted with 4-(4-aminophenyl)butan-1-ol(170 mg, 1.0 mmol) to afford desired product (140 mg, 37%) as a an oil.ESI MS m/z 439 [M+H]⁺.

Example 60N-(4-(4-bromobutyl)phenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1152)

To a solution ofN-(4-(4-hydroxybutyl)phenyl)-2-((4-methylphenyl)sulfonamido)benzamide(40 mg, 0.091 mmol) in DCM (5 mL) was added carbon tetrabromide (60 mg,0.18 mmol) and triphenylphosphine (47 mg, 0.18 mmol). The reactionstirred at rt overnight. The mixture was diluted with ethyl acetate andwater, and the aqueous layer extracted with ethyl acetate. The organiclayers were combined, dried with sodium sulfate, filtered, concentrated,and purified with silica gel chromatography to afford the desiredproduct (18 mg, 40%) as a clear oil. ESI MS m/z 502 [M+H]⁺.

Example 615-methoxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1166)

Step 1. methyl 5-methoxy-2-((4-methylphenyl)sulfonamido)benzoate(JRW-1159)

Following general procedure A, methyl 2-amino-5-methoxybenzoate (5.0 g,27.6 mmol) was reacted with 4-methylbenzenesulfonyl chloride (5.8 g,30.3 mmol) to afford crude product as a purple solid. ESI MS m/z 336[M+H]⁺.

Step 2. 5-methoxy-2-((4-methylphenyl)sulfonamido)benzoic acid (JRW-1161)

Following general procedure B, methyl5-methoxy-2-((4-methylphenyl)sulfonamido)benzoate (27.6 mmol) wasreacted with NaOH (27.6 mL, 2M, 55.2 mmol) to afford desired product(8.4 g, 94%) as a light purple solid. ESI MS m/z 322 [M+H]⁺.

Step 3. 5-methoxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1166)

Following general procedure C2,5-methoxy-2-((4-methylphenyl)sulfonamido)benzoic acid (500 mg, 1.6 mmol)was reacted with p-toluidine (200 mg, 1.9 mmol) to afford desiredproduct (348 mg, 54%) as a white foam. ESI MS m/z 411 [M+H]⁺.

Example 62N-(benzo[b]thiophen-2-yl)-5-methoxy-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1167)

Following general procedure C2,5-methoxy-2-((4-methylphenyl)sulfonamido)benzoic acid (100 mg, 0.31mmol) was reacted with benzo[b]thiophen-2-amine (51 mg, 0.34 mmol) toafford desired product (34 mg, 24%) as a light brown solid. ESI MS m/z453 [M+H]⁺.

Example 634-methoxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1202)

Step 1. methyl 4-methoxy-2-((4-methylphenyl)sulfonamido)benzoate(JRW-1195)

Following general procedure A, methyl 2-amino-4-methoxybenzoate (1.0 g,5.5 mmol) was reacted with 4-methylbenzenesulfonyl chloride (1.2 g, 6.1mmol) to afford crude product (1.9 g) as a white foam. ESI MS m/z 336[M+H]⁺.

Step 2. 4-methoxy-2-((4-methylphenyl)sulfonamido)benzoic acid (JRW-1198)

Following general procedure B, methyl4-methoxy-2-((4-methylphenyl)sulfonamido)benzoate (5.5 mmol) was reactedwith NaOH (5.6 mL, 2M, 11.3 mmol) to afford desired product (1.7 g, 94%)as a light yellow solid. ESI MS m/z 322 [M+H]⁺.

Step 3. 4-methoxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1202)

Following general procedure C2,4-methoxy-2-((4-methylphenyl)sulfonamido)benzoic acid (510 mg, 1.6 mmol)was reacted with p-toluidine (200 mg, 1.9 mmol) to afford desiredproduct (460 mg, 70%) as a white foam. ESI MS m/z 411 [M+H]⁺.

Example 64N-(benzo[b]thiophen-2-yl)-4-methoxy-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1203)

Following general procedure C2,4-methoxy-2-((4-methylphenyl)sulfonamido)benzoic acid (50 mg, 0.16 mmol)was reacted with benzo[b]thiophen-2-amine (27 mg, 1.8 mmol) to afforddesired product (30 mg, 42%) as an orange solid. ESI MS m/z 453 [M+H]⁺.

Example 65 2-((3-methoxyphenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1205)

Step 1. methyl 2-((3-methoxyphenyl)sulfonamido)benzoate (JRW-1196)

Following general procedure A, methyl 2-aminobenzoate (700 mg, 4.6 mmol)was reacted with 3-methoxybenzenesulfonyl chloride (1.05 g, 5.1 mmol) toafford desired product (1.3 g, 87%) as a white solid. ESI MS m/z 322[M+H]⁺.

Step 2. 2-((3-methoxyphenyl)sulfonamido)benzoic acid (JRW-1199)

Following general procedure B, methyl2-((3-methoxyphenyl)sulfonamido)benzoate (1.3 g, 4.1 mmol) was reactedwith NaOH (4.0 mL, 2M, 8.0 mmol) to afford crude product (1.5 g) as awhite solid. ESI MS m/z 308 [M+H]⁺.

Step 3. 2-((3-methoxyphenyl)sulfonamido)-N-(p-tolyl)benzamide (JRW-1205)

Following general procedure C2, 2-((3-methoxyphenyl)sulfonamido)benzoicacid (455 mg, 1.5 mmol) was reacted with p-toluidine (190 mg, 1.8 mmol)to afford desired product (335 mg, 57%) as a light brown solid. ESI MSm/z 397 [M+H]⁺.

Example 66N-(benzo[b]thiophen-2-yl)-2-((3-methoxyphenyl)sulfonamido)benzamide(JRW-1230)

Following general procedure C2, 2-((3-methoxyphenyl)sulfonamido)benzoicacid (60 mg, 0.19 mmol) was reacted with benzo[b]thiophen-2-amine (35mg, 0.23 mmol) to afford desired product (30 mg, 35%) as a red brownsolid. ESI MS m/z 439 [M+H]⁺.

Example 675-hydroxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1232)

To a solution of5-methoxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide (260 mg,0.63 mmol) in DCM (10 mL) was added boron tribromide (1.6 mL, 1.0M, 1.6mmol) at 0° C. The reaction warmed to rt, stirred for 18 h, and quenchedwith a saturated solution of NaHCO₃. The mixture was diluted with DCMand water, and the aqueous layer extracted with DCM. The organic layerswere combined, dried with sodium sulfate, filtered, concentrated, andpurified with silica gel chromatography to afford the desired product(29 mg, 11%) as a brown solid. ESI MS m/z 397 [M+H]⁺.

Example 68 2-((3-hydroxyphenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1236)

To a solution of 2-((3-methoxyphenyl)sulfonamido)-N-(p-tolyl)benzamide(190 mg, 0.48 mmol) in DCM (10 mL) was added boron tribromide (0.96 mL,1.0M, 0.96 mmol) at 0° C. The reaction warmed to rt, stirred for 18 h,and quenched with a saturated solution of NaHCO₃. The mixture wasdiluted with DCM and water, and the aqueous layer extracted with DCM.The organic layers were combined, dried with sodium sulfate, filtered,concentrated, and purified with silica gel chromatography to afford thedesired product (140 mg, 76%) as a light brown solid. ESI MS m/z 383[M+H]⁺.

Example 69 2-((3-butoxyphenyl)sulfonamido)-N-(p-tolyl)benzamide(JRW-1266)

To a solution of 2-((3-hydroxyphenyl)sulfonamido)-N-(p-tolyl)benzamide(40 mg, 0.10 mmol) in THE (3 mL) was added n-butanol (15 mg, 0.20 mmol),triphenylphosphine (30 mg, 0.12 mmol) and DIAD (46 mg, 0.23 mmol). Themixture stirred at rt for 18 h. The mixture was diluted with ethylacetate and water, and the aqueous layer extracted with ethyl acetate.The organic layers were combined, dried with sodium sulfate, filtered,concentrated, and purified with silica gel chromatography to afford thedesired product (30 mg, 65%) as a white solid. ESI MS m/z 439 [M+H]⁺.

Example 70 N-(2-bromophenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1282)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (200 mg, 0.68 mmol) was reacted with 2-bromoaniline (141 mg, 0.82mmol) to afford desired product (48 mg, 15%) as a white solid. ESI MSm/z 446 [M+H]⁺.

Example 71 N-(3-bromophenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1283)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (200 mg, 0.68 mmol) was reacted with 3-bromoaniline (141 mg, 0.82mmol) to afford desired product (122 mg, 40%) as a white solid. ESI MSm/z 446 [M+H]⁺.

Example 72N-([1,1′-biphenyl]-4-yl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1288)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with [1,1′-biphenyl]-4-amine (34 mg,0.20 mmol) to afford desired product (42 mg, 55%) as a white solid. ESIMS m/z 443 [M+H]⁺.

Example 73 N-(2-methoxyphenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1292)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (190 mg, 0.65 mmol) was reacted with 2-methoxyaniline (96 mg, 0.78mmol) to afford desired product (155 mg, 60%) as a light brown solid.ESI MS m/z 397 [M+H]⁺.

Example 74N-([1,1′-biphenyl]-3-yl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1297)

To a solution ofN-(3-bromophenyl)-2-((4-methylphenyl)sulfonamido)benzamide (110 mg, 0.24mmol) in dioxane (5 mL) was added phenylboronic acid (36 mg, 0.29 mmol)and Pd(dppf)Cl₂ (20 mg, 0.024 mmol). The mixture was purged withnitrogen after which aqueous Cs₂CO₃ (0.74 mL, 1 M) was added. Thereaction was heated to 80° C. for 2 h. The mixture was diluted withethyl acetate and washed with water and brine. The organic layers werecombined, dried with sodium sulfate, filtered, concentrated, andpurified with silica gel chromatography to afford the desired product(105 mg, 96%) as a white solid. ESI MS m/z 443 [M+H]⁺.

Example 75 N-(3-methoxyphenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1299)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (190 mg, 0.65 mmol) was reacted with 3-methoxyaniline (96 mg, 0.78mmol) to afford desired product (165 mg, 64%) as a white solid. ESI MSm/z 397 [M+H]⁺.

Example 76 N-(4-methoxyphenyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1300)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (190 mg, 0.65 mmol) was reacted with 4-methoxyaniline (96 mg, 0.78mmol) to afford desired product (156 mg, 60%) as a light brown solid.ESI MS m/z 397 [M+H]⁺.

Example 772-((N-ethyl-4-methylphenyl)sulfonamido)-N-(4-methoxyphenyl)benzamide(JRW-1325)

To a solution ofN-(4-methoxyphenyl)-2-((4-methylphenyl)sulfonamido)benzamide (50 mg,0.12 mmol) in DMF (3 mL) was added diisopropylethylamine (49 mg, 0.38mmol) and ethyl iodide (0.5 mL). The solution stirred for 18 h at 60° C.The mixture was diluted with ethyl acetate and washed with water andbrine. The organic layers were combined, dried with sodium sulfate,filtered, concentrated, and purified with silica gel chromatography toafford the desired product (50 mg, 94%) as a light yellow foam. ESI MSm/z 425 [M+H]⁺.

Example 78N-(benzo[b]thiophen-2-yl)-4-fluoro-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1346)

Step 1. methyl 4-fluoro-2-((4-methylphenyl)sulfonamido)benzoate(JRW-1342)

Following general procedure A, methyl 2-amino-4-fluorobenzoate (1.0 g,5.9 mmol) was reacted with 4-methylbenzenesulfonyl chloride (1.2 g, 6.5mmol) to afford the desired product (1.52 g, 79%) as a light yellowsolid. ESI MS m/z 324 [M+H]⁺.

Step 2. 4-fluoro-2-((4-methylphenyl)sulfonamido)benzoic acid (JRW-1344)

Following general procedure B, methyl4-fluoro-2-((4-methylphenyl)sulfonamido)benzoate (1.5 g, 4.6 mmol) wasreacted with NaOH (7 mL, 2 M, 14 mmol) to afford crude product (1.6 g)as a light yellow solid. ESI MS m/z 310 [M+H]⁺.

Step 3.N-(benzo[b]thiophen-2-yl)-4-fluoro-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1346)

Following general procedure C2,4-fluoro-2-((4-methylphenyl)sulfonamido)benzoic acid (100 mg, 0.32 mmol)was reacted with benzo[b]thiophen-2-amine (58 mg, 0.39 mmol) to afforddesired product (93 mg, 65%) as a light pink solid. ESI MS m/z 441[M+H]⁺.

Example 79N-(benzo[b]thiophen-2-yl)-5-fluoro-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1347)

Step 1. methyl 5-fluoro-2-((4-methylphenyl)sulfonamido)benzoate(JRW-1343)

Following general procedure A, methyl 2-amino-5-fluorobenzoate (1.0 g,5.9 mmol) was reacted with 4-methylbenzenesulfonyl chloride (1.2 g, 6.5mmol) to afford the desired product (1.9 g, 99%) as a white solid. ESIMS m/z 324 [M+H]⁺.

Step 2. 5-fluoro-2-((4-methylphenyl)sulfonamido)benzoic acid (JRW-1345)

Following general procedure B, methyl5-fluoro-2-((4-methylphenyl)sulfonamido)benzoate (1.9 g, 5.9 mmol) wasreacted with NaOH (9 mL, 2 M, 18 mmol) to afford crude product (1.8 g)as a white solid. ESI MS m/z 310 [M+H]⁺.

Step 3.N-(benzo[b]thiophen-2-yl)-5-fluoro-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1347)

Following general procedure C2,5-fluoro-2-((4-methylphenyl)sulfonamido)benzoic acid (100 mg, 0.32 mmol)was reacted with benzo[b]thiophen-2-amine (58 mg, 0.39 mmol) to afforddesired product (38 mg, 26%) as a light brown solid. ESI MS m/z 441[M+H]⁺.

Example 80 N-benzyl-2-((4-methylphenyl)sulfonamido)benzamide (JRW-1383)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with benzylamine (31 mg, 0.21 mmol)to afford desired product (6 mg, 9%) as a light brown solid. ESI MS m/z381 [M+H]⁺.

Example 81 N-(4-methoxybenzyl)-2-((4-methylphenyl)sulfonamido)benzamide(JRW-1384)

Following general procedure C2, 2-((4-methylphenyl)sulfonamido)benzoicacid (50 mg, 0.17 mmol) was reacted with 4-methoxy-benzylamine (31 mg,0.21 mmol) to afford desired product (25 mg, 35%) as a light brownsolid. ESI MS m/z 411 [M+H]⁺.

Example 82N-(benzo[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)-5-(trifluoromethyl)benzamide(JRW-1388)

Step 1. methyl2-((4-methylphenyl)sulfonamido)-5-(trifluoromethyl)benzoate (JRW-1382)

Following general procedure A, methyl2-amino-5-(trifluoromethyl)benzoate (1.0 g, 4.6 mmol) was reacted with4-methylbenzenesulfonyl chloride (0.96 g, 5.0 mmol) to afford thedesired product (1.4 g, 81%) as a white solid. ESI MS m/z 374 [M+H]⁺.

Step 2. 2-((4-methylphenyl)sulfonamido)-5-(trifluoromethyl)benzoic acid(JRW-1386)

Following general procedure B, methyl2-((4-methylphenyl)sulfonamido)-5-(trifluoromethyl)benzoate (1.4 g, 3.7mmol) was reacted with NaOH (3.7 mL, 2 M, 7.4 mmol) to afford crudeproduct (1.3 g) as a white solid. ESI MS m/z 360 [M+H]⁺.

Step 3.N-(benzo[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)-5-(trifluoromethyl)benzamide(JRW-1388)

Following general procedure C2,2-((4-methylphenyl)sulfonamido)-5-(trifluoromethyl)benzoic acid (110 mg,0.31 mmol) was reacted with benzo[b]thiophen-2-amine (55 mg, 0.37 mmol)to afford desired product (140 mg, 93%) as a light brown solid. ESI MSm/z 491 [M+H]⁺.

Example 83 Selective Inhibition of Bioluminescent Complexes

The following example provides a use for the disclosed inhibitor toselectively inhibit various bioluminescent complexes, e.g., Oplophorusluciferase-derived bioluminescent complex, without inhibiting NanoLuc®luciferase. FIG. 1A shows inhibition of the NanoBiT® HiBiT/LgBiTbioluminescent complex by exemplary compounds. NanoBiT® HiBiTnon-luminescent peptide and NanoBiT® LgBiT non-luminescent polypeptidewere diluted in PBS+0.01% BSA, respectively (final concentration of 0.1nM and 100 nM, respectively), and incubated with the serially dilutedconcentrations of the indicated compounds for 2 hours at roomtemperature in the presence of RPMI media. (2.5% FBS final) Samples wereanalyzed after addition of furimazine (10 μM final concentration) usinga GloMax®-Multi+ Plate Reader. Each sample was normalized to a “noinhibitor” control. The IC₅₀ values were then determined using GraphPadPrism (log[inhibitor] vs. normalized response). FIG. 1B shows theinhibition of the NanoBiT® SmBiT/LgBiT bioluminescent complex byexemplary compounds of the present invention. The NanoBiT® SmBiT-annexinfusion and NanoBiT® LgBiT-annexin fusion were diluted to a finalconcentration of 60 nM and 30 nM, respectively, in PBS/0.01% BSA andincubated with serially diluted concentrations of the indicatedcompounds for 2 hours at room temperature in the presence of K562 celllysate diluted into RPMI media (2.5% FBS final). Samples were analyzedafter addition of furimazine (10 μM final concentration) using aGloMax®-Multi+ Plate Reader. Each sample was normalized to a “noinhibitor” control. The IC₅₀ values were then determined using GraphPadPrism (log[inhibitor] vs. normalized response). FIG. 1C is a bar graphcomparing the calculated IC₅₀ values between the NanoBiT® HiBiT/LgBiTand SmBiT/LgBiT complexes of the exemplary compounds shown in FIGS. 1Aand 1B.

FIG. 2 compares the NANOLUC® (Nluc) inhibitory activity of exemplarycompounds of the present invention to PBI-6096, a known Nluc inhibitor.Inhibitors were diluted into CO₂-independent media with 10% FBS. Nlucwas diluted to 2 ng/ml into NanoGlo® buffer with 100 μM furimazine.Serial dilutions of the inhibitors were added to theNanoLuc/furimazine/NanoGlo® solution, and samples were immediatelyanalyzed using a GloMax®-Multi+ Plate Reader. As shown in FIG. 2,JRW-1004, HL-0005, and HL-0010 do not show any appreciable inhibitionagainst NanoLuc demonstrating the selectivity of the compounds forOplophorus luciferase-derived bioluminescent complexes.

Example 84 Inhibition of Bioluminescent Complexes in Cells

FIGS. 3A-3B show the inhibition of bioluminescent complexes in cells. InFIG. 3A, HEK293 cells were transfected with DNA encoding anintracellular NanoBiT® HiBiT fusion protein, plated at 20,000 cells/100μL growth medium, and incubated for 24 hours. Following 24 hours ofexpression, cells were lysed with 50 ug/mL (final) of digitonin inOptiMEM and treated with purified NanoBiT® LgBiT non-luminescentpolypeptide and serial dilutions of HL-0005. After 2 hours of incubationat room temperature, furimazine was added (10 μM final concentration),and luminescence was measured on a GloMax®-Multi+ Plate Reader.

In FIG. 3B, HEK293 cells were transfected with DNA encoding anintracellular NanoBiT® HiBiT fusion protein and DNA encoding anintracellular NanoBiT® LgBiT fusion protein such that the fusionproteins were co-expressed within the cell. Transfected cells wereplated at 20,000 cells/100 μL growth medium and incubated for 24 hours.Following 24 hours of expression, cells were optionally lysed with 50ug/mL of digitonin in OptiMEM and treated with serial dilutions ofHL-0005. After 2 hours of incubation at room temperature, furimazine wasadded (10 μM final concentration), and luminescence was measured on aGloMax® Multi+ Plate Reader. FIG. 3A shows inhibition of the NanoBiT®HiBit/LgBit bioluminescent complex with HL-0005 in a cellular context.FIG. 3B compares IC₅₀ values in lytic and non-lytic conditionsindicating HL-0005 is mostly cell permeable.

Example 85 Inhibitor IC₅₀ Determination

The following example provides the IC₅₀ values for the compoundsdisclosed herein. The results are shown in Table 1. NanoBiT® HiBiTnon-luminescent peptide and LgBiT non-luminescent non-polypeptide werediluted to 0.1 nM and 1 nM, respectively, in TBS buffer with 0.01% BSAto make the detection reagent. A 3× dilution series of each inhibitorwas then made in the detection reagent. A “no inhibitor” control wasalso made for each sample. 50 ul of each inhibitor dilution was mixed 6μM (final) furimazine, and luminescence was measured. Each sample wasnormalized to the “no inhibitor” control. The IC₅₀ values were thendetermined using GraphPad Prism (log[inhibitor] vs. normalized response)

TABLE 1 Identifier IC50 (uM) JRW-0998 0.043 JRW-1004 0.03 JRW-1006 1.0JRW-1008 0.24 JRW-1011 0.094 HL-0005 0.0039 HL-0006 0.21 HL-0007 0.014HL-0008 0.024 HL-0009 16 HL-0010 0.022 HL-0012 0.49 HL-0017 NA HL-00190.029 HL-0023 0.58 HL-0025 0.085 HL-0026 0.24 HL-0030 NA HL-0031 NAHL-0035 NA HL-0038 0.044 HL-0040 0.43 HL-0041 0.013 HL-0044 0.088HL-0057 0.055 HL-0059 0.19 HL-0061 0.029 HL-0062 1.2 JRW-1076 0.026JRW-1077 0.089 HL-0070 0.13 HL-0071 0.043 JRW-1090 1.1 JRW-1091 NAJRW-1107 NA JRW-1110 NA JRW-1114 0.17 JRW-1120 NA JRW-1121 NA JRW-11460.63 JRW-1150 19 JRW-1152 0.12 JRW-1154 NA JRW-1164 6.5 JRW-1166 0.13JRW-1167 0.02 JRW-1202 0.18 JRW-1203 0.1 JRW-1205 0.029 JRW-1230 0.0078JRW-1232 1.0 JRW-1236 0.033 JRW-1248 0.28 JRW-1250 0.54 JRW-1251 NAJRW-1253 2.3 JRW-1255 0.060 JRW-1261 0.17 JRW-1263 NA JRW-1266 1.5JRW-1267 0.036 JRW-1269 1.1 JRW-1268 NA JRW-1270 1.2 JRW-1271 NAJRW-1272 0.70 JRW-1273 NA JRW-1275 0.34 JRW-1282 0.20 JRW-1283 0.046JRW-1284 0.71 JRW-1285 0.36 JRW-1287 0.15 JRW-1288 0.11 JRW-1293 NAJRW-1292 0.59 JRW-1297 0.10 JRW-1299 0.090 JRW-1300 0.043 JRW-1325 1.3JRW-1327 0.36 JRW-1328 1.1 JRW-1346 0.014 JRW-1347 0.0008 JRW-1383 NAJRW-1384 NA JRW-1388 0.00058 NA—no activity NT—not tested

It is understood that the foregoing detailed description andaccompanying examples are merely illustrative and are not to be taken aslimitations upon the scope of the invention, which is defined solely bythe appended claims and their equivalents.

Various changes and modifications to the disclosed embodiments will beapparent to those skilled in the art. Such changes and modifications,including without limitation those relating to the chemical structures,substituents, derivatives, intermediates, syntheses, compositions,formulations, or methods of use of the invention, may be made withoutdeparting from the spirit and scope thereof.

APPENDIX

SEQ ID NO: 1 Native Mature Oplophorus luciferase amino acid sequenceFTLADFVGDWQQTAGYNQDQVLEQGGLSSLFQALGVSVTPIQKVVLSGENGLKADIHVIIPYEGLSGFQMGLIEMIFKVVYPVDDHHFKIILHYGTLVIDGVTPNMIDYFGRPYPGIAVFDGKQITVTGTLWNGNKIYDERLINPDGSLL FRVTINGVTGWRLCENILASEQ ID NO: 2 Wild-Type NLpep MGVTGWRLCERILA SEQ ID NO: 3Wild-Type NLpoly MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQRIVLSGENGLKIDIHVIIPYEGLSGDQMGQIEKIFKVVYPVDDHHFKVILHYGTLVIDGVTPNMIDYFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLINPDGS LLFRVTINVSEQ ID NO: 4 amino acid sequence for HiBiT VSGWRLFKKIS SEQ ID NO: 5amino acid sequence for LgBiTMVFTLEDFVGDWEQTAAYNLDQVLEQGGVSSLLQNLAVSVTPIQRIVRSGENALKIDIHVIIPYEGLSADQMAQIEEVFKVVYPVDDHHFKVILPYGTLVIDGVTPNMLNYFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLITPDGS MLFRVTINSSEQ ID NO: 6 amino acid sequence for SmBiT VTGYRLFEEIL SEQ ID NO: 7NanoLuc MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQRIVLSGENGLKIDIHVIIPYEGLSGDQMGQIEKIFKVVYPVDDHHFKVILHYGTLVIDGVTPNMIDYFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLINPDGS LLFRVTINGVTGWRLCERILA

1.-14. (canceled)
 15. A compound selected from the group consisting ofN-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide;N-(3-cyanothiophen-2-yl)-2-((4-methylphenyl)sulfonamido)benzamide;N-(2-cyanophenyl)-2-((4-methylphenyl)sulfonamido)benzamide;2-((4-methylphenyl)sulfonamido)-N-phenylbenzamide;N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-2-(phenylsulfonamido)benzamide;2-([1,1′-biphenyl]-3-sulfonamido)-N-(p-tolyl)benzamide; methyl3-(N-(2-(p-tolylcarbamoyl)phenyl)sulfamoyl)benzoate;3-(N-(2-(p-tolylcarbamoyl)phenyl)sulfamoyl)benzoic acid;2-((3-acetamidophenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-aminophenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-(hydroxymethyl)phenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-(butylcarbamoyl)phenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-bromophenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-(butylamino)phenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-(hex-1-yn-1-yl)phenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-hexylphenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-(3-hydroxyprop-1-yn-1-yl)phenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-(3-hydroxypropyl)phenyl)sulfonamido)-N-(p-tolyl)benzamide;N-(p-tolyl)-2-((4-(trifluoromethyl)phenyl)sulfonamido)benzamide;2-((4-methoxyphenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((4-bromophenyl)sulfonamido)-N-(p-tolyl)benzamide;2-([1,1′-biphenyl]-4-sulfonamido)-N-(p-tolyl)benzamide;N-(p-tolyl)-2-((3-(trifluoromethyl)phenyl)sulfonamido)benzamide;N-(p-tolyl)-2-((3-(trifluoromethoxy)phenyl)sulfonamido)benzamide;N-cyclohexyl-2-((4-methylphenyl)sulfonamido)benzamide;2-((4-methylphenyl)sulfonamido)-N-(naphthalen-2-yl)benzamide;2-((4-methylphenyl)sulfonamido)-N-(5,6,7,8-tetrahydronaphthalen-2-yl)benzamide;methyltrans-4-(2-((4-methylphenyl)sulfonamido)benzamido)cyclohexane-1-carboxylate;trans-4-(2-((4-methylphenyl)sulfonamido)benzamido)cyclohexane-1-carboxylicacid; 2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide; ethyl2-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)acetate;N-(3-isopropylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide; ethyl3-(2-((4-methylphenyl)sulfonamido)benzamido)benzoate;2-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)acetic acid;3-(2-((4-methylphenyl)sulfonamido)benzamido)benzoic acid;2-((4-methylphenyl)sulfonamido)-N-(m-tolyl)benzamide;2-((4-methylphenyl)sulfonamido)-N-(2-propylphenyl)benzamide;N-(3-butylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;N-(4-butylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;N-(4-hexylphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;2-((4-methylphenyl)sulfonamido)-N-(4-octylphenyl)benzamide; methyl6-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)hexanoate;6-(4-(2-((4-methylphenyl)sulfonamido)benzamido)phenyl)hexanoic acid;N-(4-(6-hydroxyhexyl)yl)-2-((4-methylphenyl)sulfonamido)benzamide;N-(4-(4-hydroxybutyl)phenyl)-2-((4-methylphenyl)sulfonamido)benzamide;N-(4-(4-bromobutyl)phenyl)-2-((4-methylphenyl)sulfonamido)benzamide;5-methoxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide;4-methoxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-methoxyphenyl)sulfonamido)-N-(p-tolyl)benzamide;5-hydroxy-2-((4-methylphenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-hydroxyphenyl)sulfonamido)-N-(p-tolyl)benzamide;2-((3-butoxyphenyl)sulfonamido)-N-(p-tolyl)benzamide;N-(2-bromophenyl)-2-((4-methylphenyl)sulfonamido)benzamide;N-(3-bromophenyl)-2-((4-methylphenyl)sulfonamido)benzamide;N-([1,1′-biphenyl]-4-yl)-2-((4-methylphenyl)sulfonamido)benzamide;N-(2-methoxyphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;N-([1,1′-biphenyl]-3-yl)-2-((4-methylphenyl)sulfonamido)benzamide;N-(3-methoxyphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;N-(4-methoxyphenyl)-2-((4-methylphenyl)sulfonamido)benzamide;2-((N-ethyl-4-methylphenyl)sulfonamido)-N-(4-methoxyphenyl)benzamide;N-benzyl-2-((4-methylphenyl)sulfonamido)benzamide; andN-(4-methoxybenzyl)-2-((4-methylphenyl)sulfonamido)benzamide; or a saltthereof.
 16. A method of inhibiting luciferase activity of an Oplophorusluciferase-derived bioluminescent complex, the method comprisingcontacting the bioluminescent complex with the compound of claim
 1. 17.The method of claim 16, wherein the bioluminescent complex comprises twoor more substantially non-luminescent peptide and/or polypeptide units,and wherein association of the two or more non-luminescent peptideand/or polypeptide units produces a detectable bioluminescent signal inthe presence of a coelenterazine substrate.
 18. The method of claim 17,wherein association of the two or more substantially non-luminescentpeptide and/or polypeptide units generates a bioluminescent complexcapable of binding the coelenterazine substrate.
 19. The method of claim16, wherein the bioluminescent complex comprises: a) a peptidecomprising an amino acid sequence having less than 100% and greater than40% identity to SEQ ID NO: 2; and b) a polypeptide comprising an aminoacid sequence having less than 100% and greater than 40% identity withSEQ ID NO: 3, wherein the bioluminescent complex exhibits detectableluminescence in the presence of a coelenterazine substrate.
 20. Themethod of claim 19, wherein the bioluminescent complex comprises apolypeptide having an amino acid sequence of SEQ ID NO: 5 and a peptidehaving an amino acid sequence of SEQ ID: 4 or SEQ ID NO:
 6. 21. A methodfor modulating luminescence of an Oplophorus luciferase-derivedbioluminescent complex in a sample, the method comprising: (a)contacting the sample with a coelenterazine substrate and the compoundof claim 1; and (b) detecting luminescence in the sample, wherein thecompound of claim 1 causes a decrease in the luminescence from thebioluminescent complex.
 22. A method to detect an interaction orco-localization between a first molecule and a second molecule in asample, the method comprising: (a) contacting a sample with acoelenterazine substrate and the compound of claim 1, wherein the samplecomprises: (i) a first fusion, wherein the first fusion comprises anon-luminescent peptide o polypeptide of an Oplophorus-derivedluciferase and a first molecule; and (ii) a second fusion, wherein thesecond fusion comprises a non-luminescent complementary polypeptide orpeptide of an Oplophorus-derived luciferase and a second molecule,wherein the non-luminescent polypeptide is capable of forming abioluminescent complex with the non-luminescent peptide; and (b)detecting luminescence in the sample, wherein the detection ofluminescence indicates an interaction or co-localization between thefirst molecule and the second molecule.
 23. (canceled)
 24. A method todetect an interaction or co-localization of a first molecule and asecond molecule in a sample, the method comprising: (a) contacting asample with a non-luminescent polypeptide or peptide of anOplophorus-derived luciferase, a coelenterazine substrate, and thecompound of claim 1, wherein the sample comprises: (i) a firstpolynucleotide encoding a first fusion, wherein the first fusioncomprises an non-luminescent complementary peptide or polypeptide of anOplophorus-derived luciferase and a first molecule, wherein thenon-luminescent complementary peptide or polypeptide is capable offorming a bioluminescent complex with the non-luminescent polypeptide orpeptide; and (ii) a second polynucleotide encoding a second fusion,wherein the second fusion comprises a fluorescent acceptor molecule anda second molecule; and (b) detecting bioluminescence resonance energytransfer (BRET) in the sample indicating an interaction orco-localization of the first molecule and the second molecule. 25.(canceled)
 26. A method to detect interaction or co-localization ofmolecules in a sample, the method comprising: (a) contacting a samplewith a coelenterazine substrate and the compound of claim 1, wherein thesample comprises: (i) a first fusion comprising a non-luminescentpolypeptide of an Oplophorus-derived luciferase and a first molecule;(ii) a second fusion comprising a non-luminescent peptide of anOplophorus-derived luciferase and a second molecule, wherein thenon-luminescent peptide is capable of forming a bioluminescent complexwith the non-luminescent polypeptide; and (iii) a third fusioncomprising a fluorescent acceptor molecule and a third molecule; and (b)detecting bioluminescence resonance energy transfer (BRET) in thesample, indicating an interaction or co-localization between the firstmolecule, second molecule, and third molecule in the sample.
 27. Amethod to detect a molecule of interest in a sample, the methodcomprising: (a) contacting a sample comprising the molecule of interestfused to a non-luminescent peptide or polypeptide of anOplophorus-derived luciferase with (i) a coelenterazine substrate; (ii)the compound of claim 1; and (iii) a non-luminescent complementarypolypeptide or peptide of an Oplophorus-derived luciferase, wherein thenon-luminescent complementary polypeptide or peptide is capable offorming a bioluminescent complex with the non-luminescent peptide orpolypeptide; and (b) detecting luminescence in the sample, whereindetection of luminescence indicates formation of a bioluminescentcomplex between the non-luminescent peptide and the non-luminescentpolypeptide.
 28. (canceled)
 29. A method to detect a molecule ofinterest in a sample, the method comprising: (a) contacting a samplecomprising the molecule of interest fused to a non-luminescent peptideor polypeptide of an Oplophorus-derived luciferase with (i) acoelenterazine substrate; (ii) a compound of claim 1; and (iii) a fusioncomprising a non-luminescent complementary polypeptide or peptide of anOplophorus-derived luciferase and a fluorescent moiety, wherein thenon-luminescent complementary polypeptide or peptide is capable offorming a bioluminescent complex with the non-luminescent peptide orpolypeptide; and (b) detecting bioluminescence resonance energy transfer(BRET) in the sample, indicating detection of the molecule. 30.-35.(canceled)
 36. A bioluminescence resonance energy transfer (BRET) systemcomprising: (a) a first fusion comprising a non-luminescent peptide orpolypeptide of an Oplophorus-derived luciferase and a first molecule;(b) a second fusion comprising a non-luminescent complementarypolypeptide or peptide of an Oplophorus-derived luciferase and afluorescent moiety, wherein the non-luminescent complementarypolypeptide or peptide is capable of forming a bioluminescent complexwith the non-luminescent peptide or polypeptide; (c) a coelenterazinesubstrate; and (d) the compound of claim
 1. 37. (canceled)
 38. Abioluminescence resonance energy transfer (BRET) system comprising: (a)a first fusion comprising a first molecule and a non-luminescent peptideo polypeptide of an Oplophorus-derived luciferase; (b) a second fusioncomprising a second molecule and a fluorescent acceptor molecule; (c) anon-luminescent complementary polypeptide or peptide ofOplophorus-derived luciferase capable of forming a bioluminescentcomplex with the non-luminescent peptide o polypeptide of anOplophorus-derived luciferase; (d) a coelenterazine substrate; and (e)the compound of claim
 1. 39.-40. (canceled)
 41. A kit comprising: (a)the compound of claim 1; and (b) an Oplophorus luciferase-derivedbioluminescent complex.
 42. The kit of claim 41, wherein the Oplophorusluciferase-derived bioluminescent complex comprises: (a) anon-luminescent peptide comprising an amino acid sequence having lessthan 100% and greater than 40% sequence identity with SEQ ID NO: 2; and(b) a non-luminescent polypeptide comprising an amino acid sequencehaving less than 100% and greater than 40% sequence identity with SEQ IDNO:
 3. 43. A kit comprising: (a) the compound of claim 1; and (b) afirst polynucleotide encoding a non-luminescent peptide of anOplophorus-derived luciferase; and (c) a second polynucleotide encodinga non-luminescent polypeptide of an Oplophorus-derived luciferase,wherein the non-luminescent polypeptide is capable of forming abioluminescent complex with the non-luminescent peptide.
 44. The kit ofclaim 43, wherein the non-luminescent peptide comprises an amino acidsequence having less than 100% and greater than 40% sequence identitywith SEQ ID NO: 2; and the non-luminescent polypeptide comprises anamino acid sequence having less than 100% and greater than 40% sequenceidentity with SEQ ID NO:
 3. 45. The kit of claim 41, further comprisinga coelenterazine substrate.
 46. The kit of claim 43, further comprisinga coelenterazine substrate.